

## Review

# Expression of neuropeptides and their receptors in the developing retina of mammals

P. Bagnoli<sup>1</sup>, M. Dal Monte<sup>1</sup> and G. Casini<sup>2</sup>

<sup>1</sup>Dipartimento di Fisiologia e Biochimica "G.Moruzzi", Università di Pisa, Pisa, Italy and

<sup>2</sup>Dipartimento di Scienze Ambientali, Università della Tuscia, Viterbo, Italy

**Summary.** The present review examines various aspects of the developmental expression of neuropeptides and of their receptors in mammalian retinas, emphasizing their possible roles in retinal maturation. Different peptidergic systems have been investigated with some detail during retinal development, including substance P (SP), somatostatin (SRIF), vasoactive intestinal polypeptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), neuropeptide Y (NPY), opioid peptides and corticotrophin-releasing factor (CRF). Overall, the developmental expression of most peptides is characterized by early appearance, transient features and achievement of the mature pattern at the time of eye opening. Concerning possible developmental actions of neuropeptides, recent studies imply a role of SP in the modulation of cholinergic neurotransmission in early postnatal rabbit retinas, when cholinergic cells participate in the retinal spontaneous waves of activity. In addition, the presence of transient SRIF expressing ganglion cells and recent observations in SRIF receptor knock-out mice indicate variegated roles of this peptide in the development of the retina and of retinofugal projections. Furthermore, VIP and PACAP exert protective and growth-promoting actions that may sustain retinal neurons during their development, and opioid peptides may control cell proliferation in the developing retina. Finally, a peak in the expression of certain peptides, including VIP, NPY and CRF, is present around the time of eye opening, when the retina begins the analysis of structured visual information, suggesting important roles of these peptides during this delicate phase of retinal development. In summary, although the physiological actions of peptides during retinal development are far from being clarified, the data reviewed herein indicate promising perspectives in this field of study.

**Key words:** Peptidergic systems, Retinal cells, Maturation, Tropic actions

### Introduction

The identification of peptide signaling molecules began in the first half of the last century with substance P (SP; Hökfelt et al., 2001) and it has proceeded during the last 30 years with the discovery of numerous peptides, the characterization of their receptors and the exploitation of their physiological actions in the body. Peptidergic messengers were originally isolated (mainly) from the gut or from the hypothalamus and they were interpreted as gastrointestinal or hypothalamic hormones. However, it soon appeared that peptides are distributed to different organs or systems, including the nervous system where they have been designated "neuropeptides" (Hökfelt et al., 2000). Peptides are present in all parts of the nervous system, although each peptide has its unique pattern of distribution. Initially, it was assumed that these "peptidergic" systems were different from and complementary to previously transmitter-characterized neurons, for example those of the catecholamine and serotonin systems. Therefore, an important perspective on neuropeptides, and on chemical transmission in general, was added with the recognition that peptides almost always coexist with one or more classic transmitters (Lundberg, 1996). Functionally, neuropeptides act as neuromodulatory substances, presumably released extrasynaptically. Generally speaking, neuropeptides act on specific receptors to modulate the functional properties of neurons, such as their membrane excitability or their signal transduction pathways. Modern techniques of neuropeptide localization, molecular biology approaches, and the use of transgenic animals have prompted an enormous growth in the knowledge of neuropeptide expression and neuropeptide receptor pharmacology and diversity. However, in spite of the wide variety of information gathered on peptidergic systems and the availability of ultra-sensitive techniques, it has been difficult to define

an exact physiological role for many of the neuropeptides in the nervous system. There are, of course, examples of neuropeptide participation in specific functions or hints of neuropeptide involvement in certain behavioral states or mental diseases. For instance, SP and opioid peptides are involved in the transmission and modulation of pain (Harrison and Geppetti, 2001; Przewlocki and Przewlocka, 2001); SP and its receptor (the neurokinin 1 receptor, NK1) are implicated in depression (Harrison and Geppetti, 2001; Rupniak, 2002) and in memory-promoting, reinforcing and anxiolytic-like effects (Hasenohrl et al., 2000); SP, colecystokinin and opioid peptides participate in the regulation of aggressive behavior (Siegel et al., 1999); opioid peptides may regulate striatal output pathways and motor behavior (Steiner and Gerfen, 1998); pituitary adenylate cyclase-activating polypeptide (PACAP) is involved in the regulation of hypothalamic neurosecretion, homeostatic control of circadian clock and learning and memory processes (Zhou et al., 2002); vasoactive intestinal polypeptide (VIP) modulates the strength of glutamate-mediated neurotransmission in the cortex (Magistretti et al., 1998); somatostatin (somatotropin release-inhibiting factor, SRIF) affects electrophysiological properties of neurons and modulates classical neurotransmission with effects on cognitive, locomotor, sensory, and autonomic functions (Patel, 1999); corticotropin releasing factor (CRF) is implicated in stress-related disorders such as anxiety and depression (Reul and Holsboer, 2002), in learning and memory (Croiset et al., 2000), in pain and analgesia (Lariviere and Melzack, 2000) and in the modulation of ingestive behavior (Heinrichs and Richard, 1999); and neuropeptide Y (NPY) may have a role in neuronal excitability, learning and memory, anxiety-related behaviors, feeding, regulation of blood pressure and circadian rhythm (Thorsell and Heilig, 2002). Given the wide spectrum of (possible) neuropeptide actions, a novel approach in the study of neuropeptides has been undertaken in recent years based on the production of peptide analogs with agonistic or antagonistic properties. These lines of research have produced a variety of peptide and nonpeptide agonists and antagonists that are specific for distinct peptide receptor subtypes, including SP (Hökfelt et al., 2001), SRIF (Hannon et al., 2002), VIP (see for instance Levy et al., 2002; Reed et al., 2002), CRF (Takahashi, 2001) and TRH (Kubek and Garg, 2002) receptors. These compounds constitute important new tools to investigate the functional roles of neuropeptides and the pharmacology of their receptors. In addition, the study of peptide analogs may lead to the development of compounds with therapeutic potential in a variety of disease states. For instance, SP antagonists at the NK1 receptor have been revealed as effective antidepressant and anxiolytic agents (Hökfelt et al., 2001; Rupniak, 2002).

Besides their multifaceted actions in the mature animal, neuropeptides may play functional roles of fundamental importance during the maturation of the

nervous system. This idea may arise considering that, in the developing nervous system, neuropeptides, along with their receptors, are usually expressed at early times, when synaptic connections are still immature. In addition, transient expression of neuropeptides or developmentally regulated peptide expression have been reported in distinct brain regions, suggesting peptides may mediate functional interactions associated with the morphological and functional development of the nervous system. During this period, neuropeptides may affect a variety of parameters, including cell division, neuronal survival, neurite sprouting, growth cone motility, and neuronal and glial phenotype (Emerit et al., 1992; Müller et al., 1995; DiCicco-Bloom et al., 1998, 2000; Gressens, 1998; Hauser and Mangoura, 1998; Lindholm et al., 1998; Raffa, 1998; Schwartz et al., 1998; Yew et al., 1999; Gozes and Brenneman, 2000; Kwong et al., 2000; Hansel et al., 2001a,b; Waschek, 2002). Some of these actions are direct while others are mediated by the production of neurotrophic factors from glial cells (Gozes and Brenneman, 2000). Neuroprotective and/or neural growth-related actions have been well documented for tachykinin peptides, VIP, PACAP, SRIF, NPY and opioid peptides (Emerit et al., 1992; DiCicco-Bloom et al., 1998; Gressens, 1998; Hauser and Mangoura, 1998; Raffa, 1998; Schwartz et al., 1998; Gozes and Brenneman, 2000; Hansel et al., 2001a, b; Waschek, 2002; Zagon et al., 2002; Zhou et al., 2002).

The present paper will focus on the relevant aspects of neuropeptide expression during development in a specific region of the central nervous system, the retina. A comprehensive examination of the peptidergic systems of the brain or a detailed description of the peptidergic cell populations of the mature retina are far beyond our scopes, and these aspects have been extensively treated in many recent and past review works. However, before presenting the available data on neuropeptide expression in developing retinas, we think it is necessary to briefly recapitulate the main peptidergic systems in view of their possible roles in neural development and to summarize the organizational plan of the mammalian retina as well as its development.

### **Peptidergic systems and neural development**

In this section, main peptidergic systems which have been found to be involved in developmental processes of the nervous system will be summarized. Data of the retina are not reported, as they will be reviewed in more detail in the following paragraphs.

#### *Tachykinin peptides*

The family of tachykinin peptides includes SP, neurokinin A, neurokinin A-related peptides (neuropeptide K and neuropeptide  $\gamma$ ) and neurokinin B. Two distinct, structurally related genes encode for these peptides: SP, neurokinin A and neurokinin A-related

peptides are the protein products of the preprotachykinin A gene, while neurokinin B is encoded by the preprotachykinin B gene (Otsuka and Yoshioka, 1993). The cellular actions of the tachykinin peptides are mediated by specific, high affinity receptors. The tachykinin peptides SP, neurokinin A and neurokinin B are the preferred ligands for the neurokinin receptors, belonging to the superfamily of G protein-coupled receptors and termed NK1, NK2 and NK3, respectively (Otsuka and Yoshioka, 1993).

The preprotachykinin A is expressed early in the embryonic development of the nervous system (MacKenzie and Quinn, 2002), while the expression of NK1 receptor mRNA has been reported to be developmentally regulated in distinct regions of the rat brain (Taoka et al., 1996), suggesting a role of SP in brain development. This hypothesis is supported by observations of neuroprotective and growth-promoting actions of SP in a variety of models of the nervous system. Indeed, SP has been shown to counteract the depletion of cortical noradrenergic terminal projections induced by 6-hydroxydopamine administration in newborn rats (Jonsson and Hallman, 1982) and in kittens (Nakai and Kasamatsu, 1984), suggesting that SP may prevent cortical neuronal damage during development. In addition, SP enhances nerve growth factor-mediated neurite outgrowth (Narumi and Fujita, 1978), while SP binding sites have been shown in a growth cone-enriched fraction of developing rat forebrain (Lockerbie et al., 1988). Furthermore, SP has been reported to promote neurite outgrowth in cultured spinal cord of rat embryos (Iwasaki et al., 1989), and SP released by pioneering pathways may interact with NK1 receptors expressed by cells in the floor plate to promote the release of a chemoattractant to guide the permanent axons (De Felipe et al., 1995). Together, these data suggest that SP may act as a growth factor during the development of the nervous system.

### *SRIF*

SRIF was first identified in the hypothalamus as a tetradecapeptide that inhibited the release of growth hormone (Brazeau et al., 1973). SRIF is best regarded as a phylogenetically ancient multigene family of peptides with two important bioactive products, SRIF-14, the form originally identified in the hypothalamus, and SRIF-28, a congener of SRIF-14 extended at the N-terminus that was discovered subsequently (Pradayrol et al., 1980). SRIF-28 accounts for 20-30% of total immunoreactive SRIF in the brain, but it is not clear whether it is cosynthesized with SRIF-14 or whether it is produced in separate neurons (Patel, 1999). SRIF-14 predominates in pancreatic islets, stomach, and neural tissues and is virtually the only form in retina, peripheral nerves, and enteric neurons (Patel, 1999). SRIF-positive neurons and fibers are widely distributed throughout the central nervous system with the notable exception of the cerebellum (Johansson et al., 1984).

Five different SRIF subtype receptors have been cloned and designated  $sst_1$  through  $sst_5$  receptors (Patel, 1999). Although there is a high degree of sequence and structural homology among different SRIF receptors, they differ in their pharmacological and functional properties. For instance,  $sst_1$  and  $sst_2$  receptors differ in their affinity to specific SRIF agonists and in their modes of transmembrane signaling (Csaba and Dournaud, 2001). Both  $sst_1$  and  $sst_2$  receptors are coupled to inhibition of adenylate cyclase, but  $sst_2$  receptor, and not  $sst_1$  receptor, internalizes or desensitizes after exposure to the agonist. These diversities may underlie different functional roles of the two receptors. In particular, although both  $sst_1$  and  $sst_2$  receptors are involved in regulation of growth hormone secretion (Lanneau et al., 2000),  $sst_1$  receptor may also act as an autoreceptor and inhibit SRIF release (Helboe et al. 1998). In addition, activation of  $sst_1$  receptor increases nerve cell responses to glutamate whereas activation of  $sst_2$  receptor results in a decrease of glutamate sensitivity (Lanneau et al. 1998). Moreover,  $sst_2$  receptor, but not  $sst_1$  receptor, has been reported to regulate  $Ca^{2+}$  influx through voltage-gated  $Ca^{2+}$  channels (Petrucci et al., 2000).

In prenatal neurons, SRIF and its receptors are expressed early and transiently, but little is known about their function at these early stages (Leroux et al., 1995). The early expression of SRIF and of its receptors may indicate that this peptidergic system participates in the control of neuronal maturation (Bulloch, 1987; Grimm-Jorgensen, 1987; Gonzalez et al., 1992; Taniwaki and Schwartz, 1995; Schwartz et al., 1998; Traina et al., 1998). A variety of studies support a developmental role for SRIF by documenting its early onset, its transient expression and its morphogenetic effects. In particular, SRIF enhances neurite outgrowth (Bulloch, 1987; Grimm-Jorgensen, 1987; Taniwaki and Schwartz, 1995), potentiates the expression of  $K^+$  and  $Ca^{2+}$  channels (Rhie et al., 1999) and influences neuronal migration (Yacubova and Komuro, 2002). In addition, alterations of endogenous SRIF levels have been shown to severely affect neuronal maturation (Kungel et al., 1997; Fontanesi et al., 1998).

### *VIP and PACAP*

VIP and PACAP are members of the secretin/glucagon/VIP/PACAP/growth-hormone-releasing hormone family (Zhou et al., 2002). VIP is a 28-amino acid peptide, which was first isolated from the gastrointestinal tract (Said and Mutt, 1970). VIP and the related neuroactive peptide, peptide histidine isoleucine are synthesized from the same precursor mRNA and are derived from a common precursor protein (Itoh et al., 1983). Two PACAP isoforms have been described, one with 27 (PACAP-27) and one with 38 (PACAP-38) amino acids. PACAP-27 is identical to the N-terminal of PACAP-38 (Zhou et al., 2002).

VIP and PACAP receptors belong to the same family

of G protein-coupled receptors. Two types of binding sites for PACAP have been described. In type I sites PACAP binds with high affinity and VIP with a much lower affinity, while type II binding sites have similar affinity for PACAP and VIP. Molecular cloning has revealed three distinct PACAP receptor subtypes: a PACAP-specific PAC1 receptor, and two receptors with similar affinity for PACAP and VIP, denominated VPAC1 and VPAC2 receptors, with VPAC2 receptors also displaying high affinity for helodermin. Eight splice variants of the PAC1 receptor originate from a common gene by alternative splicing. PAC1 receptors are functionally coupled to adenylyl cyclase and to phospholipase C, while VPAC1 and VPAC2 receptors are primarily coupled to adenylyl cyclase (Zhou et al., 2002).

A developmental regulation of VPAC1 has been reported in mouse brain, suggesting a role for VIP in neuronal differentiation (Karacay et al., 2000). In fact, past and recent studies have established growth factor and neuroprotective roles for VIP. It promotes mitosis, growth and survival of immature neuronal elements in culture (Brenneman et al., 1985; Brenneman and Eiden, 1986; Pincus et al., 1990; Iwasaki et al., 2001), it is an important regulator of embryonic growth (Gressens et al., 1993; Spong et al., 1999) and it has resulted effective in protecting neural cells in a variety of situations (Gozes et al., 1996; Gressens et al., 1997; Zupan et al., 2000). These positive actions of VIP are likely to be mediated by factors released by glial cells upon VIP stimulation, including activity-dependent neurotrophic factor and related proteins (Gozes and Brenneman, 2000) and insulin growth factor-I (Servoss et al., 2001).

Trophic and protective action in the nervous system are also exerted by PACAP (Waschek et al., 2000). The expression of both PACAP and PAC1 receptor is developmentally regulated in the rat brain (Lindholm et al., 1998; Jaworski and Proctor, 2000). In addition, PACAP has been reported to regulate neurogenesis in the cerebral cortex (DiCicco-Bloom et al., 1998; Suh et al., 2001), in the cerebellum (Vaudry et al., 1999), in the olfactory epithelium (Hansel et al., 2001a) and in the superior cervical ganglion (DiCicco-Bloom et al., 2000). Interestingly, while PACAP exhibits an anti-mitogenic activity in the cerebral cortex (DiCicco-Bloom et al., 1998; Suh et al., 2001), it stimulates mitoses in the cerebellar cortex (Vaudry et al., 1999). There is also evidence of neuroprotective effects of PACAP against apoptotic cell death induced by different factors in cerebellar neurons (Vaudry et al., 2002a, b). In addition, PACAP increases the survival and promotes neurite outgrowth of cultured dorsal root ganglia neurons, where it also induces expression of calcitonin gene-related peptide (Lioudyno et al., 1998). Finally, both PACAP and VIP have been reported to affect the morphological development of cultured sympathetic neurons (Drahushuk et al., 2002).

Together, these data strongly support the evidence for important regulatory actions of both PACAP and VIP

in the development of the nervous system.

### NPY

NPY is a member of a peptide family that also includes the hormones peptide YY and pancreatic polypeptide (Larhammar, 1996). These peptides act on a common set of G protein-coupled receptors designated NPY receptors (Michel et al., 1998). Functional studies with agonists and molecular cloning have identified five different NPY receptor subtypes designated Y1, Y2, Y4, Y5 and Y6, while the existence of a Y3 receptor has also been postulated (Michel et al., 1998). These receptors act through the inhibition of adenylyl cyclase and signaling responses in neurons include inhibition of  $Ca^{2+}$  channels (Michel et al., 1998).

NPY is broadly expressed in the developing nervous system and is maintained at moderately high levels in the adult (Danger et al., 1990). NPY expression is transiently upregulated, during development, in specific compartments of the rat inferior olivary complex, supporting the hypothesis that NPY may exert different trophic-differentiating and/or neuromodulatory roles during development of this structure (Morara et al., 1997). NPY is a potent inducer of neuronal proliferation in the olfactory epithelium (Hansel et al., 2001a,b). In addition, NPY expressed by Schwann cell precursors might have a role in axonal growth or axonal guidance (Ubink and Hökfelt, 2000). The effects of NPY on growing axons may be indirect, as demonstrated in primary cultures of adult rat DRG: in this case, NPY stimulates the release of NT-3 from spinal cord slices in the same culture, which in turn stimulates neurite outgrowth from DRG neurons (White, 1998). Finally, in neurons cultured from the developing suprachiasmatic nucleus, where GABA is an excitatory transmitter, NPY exerts a long-term depression of GABA-mediated  $Ca^{2+}$  rises, suggesting that NPY-secreting cells may modulate the effects of GABA on neurite outgrowth, gene expression, and physiological stimulation (Obrietan and van den Pol, 1996).

### Opioid peptides

The family of opioid peptides is composed of a multiplicity of endogenous opioid ligands that activate G protein-coupled receptors denominated  $\mu$ ,  $\delta$ ,  $\kappa$  and  $\epsilon$ . In particular, endomorphin-1 and endomorphin-2 act on  $\mu$ -opioid receptors, enkephalins act on  $\delta$ -opioid receptors, dynorphin-A<sub>1-17</sub> acts on  $\kappa$ -opioid receptors, and  $\beta$ -endorphin acts on  $\epsilon$ -opioid receptors (Nock et al., 1993; Tseng et al., 1995).

Opioid peptides act as growth factors in neural and non-neural cells and tissues. In particular, [Met<sup>5</sup>]-enkephalin plays an important role as a tonic inhibitor regulating cell proliferation and tissue organization during development. It acts on a specific receptor that is different from the other previously identified opioid receptors. The biology of this peptide, denominated

"opioid growth factor" and of its receptor have been recently reviewed (Zagon et al., 2002).


#### Other peptides

A number of other peptides have been postulated to exert some effects on neural development in different models of the nervous system. For instance, CRF may be involved in regulating the development of mouse cerebellar neurons and glia immediately after birth (Ha et al., 2000; Bishop, 2002), and the CRF antagonist,  $\alpha$ -helical CRF, has a neuroprotective effect in ischemic or excitotoxic injury of the brain (Lyons et al., 1991; Strijbos et al., 1994). In addition, angiotensin peptides inhibit neurite outgrowth in embryonic chick sympathetic neurons in culture (Reed et al., 1996), while cholecystinin may exert neuroprotective actions in development, as it protects adult sympathetic neurons from 6-hydroxydopamine-induced lesions in mice (Manni et al., 2001). Finally, galanin has been postulated to be involved in processes taking place during brain maturation (Burazin et al., 2000).


#### The retina and its development

The vertebrate retina has been extensively used as an experimental model of the central nervous system for many years. The retina displays the complexity typical of the brain while having an ordered, layered structure that is conserved throughout its extension (Fig. 1). It is part of the central nervous system and it is separated at the same time, allowing easy experimental approaches. Its location within the eye makes the *in vivo* situation quite similar to an *in vitro* setup, in which the eye chamber may be regarded as a "natural incubator" of the retinal tissue and the vitreous humor as a culture medium that can be easily manipulated by, for instance, intraocular injections of pharmacological agents.

The structure and organization of the vertebrate retina has been extensively reviewed (for recent reviews see Bloomfield and Dacheux, 2001; Kolb et al., 2001; Masland, 2001a,b). The retina is composed of five classic neuronal cell types, including photoreceptors, bipolar, horizontal, amacrine, and ganglion cells. A sixth type is that of interplexiform cells, that may be considered an amacrine cell variant (Wässle and Boycott, 1991). The basic circuitry within the retina directs the flow of visual information from photoreceptor cells, through bipolar cells, to ganglion cells. Two horizontal pathways modulate this flow: one provided by horizontal cells in the outer retina, the other formed by amacrine cells in the inner retina (Fig. 2). Ganglion cells are the only output neurons in the retina and their axons constitute the retinofugal projections to the brain. A wide variety of neuroactive substances are expressed in the retina. The most heterogeneous retinal cell type is that of amacrine cells. They can be divided into numerous sub-populations on the basis of their neurochemical phenotypes.



**Fig. 1.** Structure of the mammalian retina. Retinal layers: POS, photoreceptor outer segments; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer; NFL, nerve fiber layer. Retinal cells: AC, amacrine cell; BC, bipolar cell; C, cone; DAC, displaced amacrine cell; GC, ganglion cell; HC, horizontal cell; IC, interplexiform cell; R, rod. Arrow indicates the direction of incoming light.



**Fig. 2.** Visual information flows through synapses between photoreceptors, bipolar cells and ganglion cells (arrows). This vertical pathway is modulated at two distinct levels by horizontal and amacrine cells (arrowheads). Abbreviations as in figure 1.

*Retinal layers and neuronal subtypes*

The layered structure of the retina and the retinal neuronal cell types are depicted in figure 1. The outermost retinal layer is that of the photoreceptor outer segments, followed (proceeding toward the vitreous chamber) by the outer nuclear layer which is formed by the photoreceptor (rods and cones) somata. The outer plexiform layer (OPL) contains the synaptic contacts between photoreceptors, bipolar cell dendrites and horizontal cells. Bipolar cells can be functionally divided into two main types, ON and OFF, according to their response to light. Morphologically, ON and OFF types are distinguished by the location of their terminal arborizations in the inner plexiform layer (IPL; see below): ON-type bipolar cells arborize in sublamina *b* (proximal half), while OFF-type bipolar cells arborize in sublamina *a* (distal half) of the IPL (Euler and Wässle, 1995; Hartveit, 1997). Bipolar cells can also be distinguished in rod bipolar cells and cone bipolar cells, according to the type of photoreceptor they contact. There is only one type of rod bipolar cell and it displays ON responses (Wässle et al., 1991), while according to a recent review (Masland, 2001b) mammalian retinas may contain between 9 and 11 different types of cone bipolar cells which represent either ON or OFF functional types. In most mammals, there are two morphologically distinct types of horizontal cells (Masland, 2001b). Proximal to the OPL, the inner nuclear layer (INL) contains the cell bodies of horizontal, bipolar, amacrine and interplexiform cells. Typically, horizontal and bipolar somata are located in the half of the INL near the OPL, while amacrine cells are located near the IPL. The main morphological characteristic to differentiate amacrine cells into two broad categories is the extension of their dendritic fields, and they can be grouped into narrow- or wide-field amacrine cells (Brecha et al., 1991). In fact, amacrine cells represent the most variegated cell type in the retina, with 29 different identified subtypes (Masland, 2001b) composed of morphologically and neurochemically distinct populations. If glutamate is the neurotransmitter of the vertical retinal pathways (photoreceptor to bipolar cells to ganglion cells), many different neuroactive substances are used by amacrine cells. Broad populations of amacrine cells are those represented by glycinergic and GABAergic amacrine cells. Among GABAergic amacrine cells, a number of subpopulations are defined on the basis of the coexistence of GABA together with another neuroactive substance (Strettoi and Masland, 1996). For instance, the "starburst" amacrine cells contain both acetylcholine and GABA (Brecha et al., 1988), while others are characterized by the presence of a specific peptide (see for instance Hutsler and Chalupa, 1994; Vigh et al., 2000; Cristiani et al., 2002). In the IPL, the synaptic contacts between bipolar cell axons, ganglion cell dendrites and amacrine cell processes are contained. Within the IPL, five sublayers, called "laminae" (Cajal, 1893), can be identified. In the

ganglion cell layer (GCL) 10-15 different types of ganglion cells have been described, and they differ both in morphology and in physiology (Masland, 2001b). Up to 18 different types of ganglion cells have been recognized in the human retina (Kolb et al., 1992). The ganglion cell axons run within the nerve fiber layer (NFL) and they converge toward the optic disk to form the optic nerve.

*Retinal development*

The development of mammalian retinas proceeds under the harmonic control of genetic and epigenetic factors which co-operate to achieve a suitable morpho-functional organization of retinal circuitry to efficiently analyze the visual environment. In the embryonic period, the proper cell types in the proper ratio are produced. Subsequently, they migrate to the proper layer, differentiate, form synaptic connections and establish their functional properties (Garey, 1984; Nishimura and Rakic, 1987; Kalil, 1990; Messersmith and Redburn, 1993; Rich et al., 1997; Provis et al., 1998; Cook and Chalupa, 2000; Mey and Thanos, 2000; Livesey and Cepko, 2001; Reese and Galli-Resta, 2002). Processes such as the acquisition of characteristic neurochemical phenotypes or the maturation of cell morphology may require an extended postnatal period and they are mostly achieved around the time of eye opening (Ferriero and Sagar, 1987, 1989; Zhang et al., 1990; Zhang and Yeh, 1991; Casini et al., 1994, 1997b, 1998; Rich et al., 1997; Lyser et al., 1999; Greka et al., 2000; Johansson et al., 2000a,b; Bai et al., 2001), although some characteristics are not fully developed until very late developmental periods. For instance, the complete morphological features of dopaminergic amacrine cells and of rod bipolar cells in the rabbit retina are achieved well after eye opening (Casini and Brecha, 1992a; Casini et al., 1996).

In the rabbit retina, a few synaptic specializations in the IPL are observed prenatally (Greiner and Weidman, 1982), and a low density of synaptic contacts is reported during the first postnatal week (McArdle et al., 1977). Between postnatal day (PND) 9 and PND 11 there is a major increase in the synaptic density, which becomes comparable to that in the adult by PND 20 (McArdle et al., 1977). The rapid phase of the increase in synaptic density in the IPL roughly corresponds to the time of eye opening (around PND 10). Functionally, by PND 10 the majority of ganglion cells can be activated by light, and their receptive field characteristics are mature by PND 20 (Masland, 1977). Similarly, in rat retinas the peak of synaptic formation in the IPL is reported around PND 12 (Horsburg and Sefton, 1987; Sassoè-Pognetto and Wässle, 1997), while eye opening is around PND 15. Before eye opening there is also a consistent remodeling of ganglion cell dendrites in the IPL (Yamasaki and Ramoa, 1993) and ganglion cell death that in the rat encompasses the first ten postnatal days (Potts et al., 1982; Perry et al., 1983). The presence of synaptic



Feller et al., 1996; Koulen, 1997; Sandmann et al., 1997; Camargo De Moura Campos and Hokoç, 1999) and GABA as well as NMDA receptors are present in the early postnatal rat retina (Hartveit et al., 1994; Sassoè-Pognetto and Wässle, 1997; Koulen et al., 1996, 1997, 1998a,b).

A characteristic of developing vertebrate retinas is the presence of the spontaneous "waves" of activity in the inner retina. Indeed, spontaneous electric activity leading to synchronized oscillations in intracellular  $Ca^{2+}$  concentration has been reported in amacrine and ganglion cells of developing retinas (Wong, 1995, 1998; Wong et al., 1995). Correlated firing of retinal ganglion cells is likely to contribute to the formation of correctly organized ganglion cell projections onto primary visual targets in the brain (Goodman and Shatz, 1993; Katz, 1993; Wong et al., 1993). Different transmitter systems may be responsible for different phases of spontaneous wave activity (Wong et al., 2000; Zhou and Zhao, 2000; Zhou, 2001a), although cholinergic mechanisms seem to play a central role (Zhou, 2001b; Feller, 2002).

#### Summary of peptidergic systems in mammalian retinas

Several peptidergic systems are expressed in mammalian retinas. In this paragraph, we will briefly summarize the main aspects of peptide expression in mammalian retinas.

Neuropeptides are generally localized in the inner retina and they are expressed by amacrine, displaced amacrine and ganglion cells. Neuropeptide receptors are widely expressed by numerous retinal cell populations, suggesting that peptidergic cells participate in multiple circuits mediating visual information processing. The differences observed between the localization of peptide-containing processes and the distribution of peptide receptors suggest that peptides act in a paracrine manner and have a broad influence on retinal circuits both in the outer and in the inner retina. Functional studies show that exogenous application of peptides modulates transmitter release from the retina (Bruun and Ehinger, 1993; Dal Monte et al., 2003a) and influences the cellular activity of bipolar, amacrine and ganglion cells (Zalutsky and Miller, 1990a,b). The signal transduction

via G-protein-coupled receptors determines the activation/inactivation of multiple intracellular effectors, including cAMP and  $Ca^{2+}$ , and the modulation of  $K^+$  and  $Ca^{2+}$  channels, and of GABAA receptors (Colas et al., 1992; Veruki and Yeh, 1992; Bruun et al., 1994; Feigenspan and Bormann, 1994; Akopian et al., 2000; Johnson et al., 2001; Petrucci et al., 2001). Peptides are often co-expressed with GABA in populations of wide-field amacrine cells. For instance, co-localization of GABA with NPY, SP or VIP has been reported in amacrine cell types of rat, rabbit, cat and monkey retinas (Vaney et al., 1989; Caruso et al., 1990; Casini and Brecha, 1992c; Cuenca and Kolb, 1998; Oh et al., 2002). In addition, PACAP is co-expressed with glutamate in ganglion cells projecting to the suprachiasmatic nucleus of the hypothalamus (Hannibal et al., 2000).

Peptidergic systems identified in mammalian retinas include tachykinin peptides, VIP, PACAP, SRIF, NPY, opioid peptides, CRF, TRH, angiotensin and others (Table 2). Recent data on peptide receptor localization allow a better understanding of peptidergic influences within the retina. For instance, NK1 receptors, whose preferred ligand is SP, are localized to dopaminergic amacrine cells both in rat (Casini et al., 1997a) and in rabbit (Casini et al., 2002) retinas. This finding is consistent with the observation that SP or an SP agonist elicit dopamine release in the rabbit retina, while an SP antagonist significantly reduces basal dopamine levels (Casini et al., submitted), suggesting that dopamine levels in the retina are strictly controlled by the SP-expressing amacrine cell population. Interestingly, the expression pattern of NK1 receptors varies among species. In the rat retina, for example, NK1 is mainly expressed by GABAergic interplexiform and amacrine cells, by adrenergic and most of the dopaminergic amacrine cells (Casini et al., 1997a), whereas in the rabbit retina it is expressed in a distinct population of cone bipolar cells and in all the dopaminergic amacrine cells (Casini et al., 2002). These differences are likely to be related to species-specific behavioral habits.

SRIF receptors have also been carefully investigated in the retina. Immunocytochemical data show that they are expressed by numerous cell populations, suggesting SRIF actions at multiple levels of retinal circuitry. In

**Table 2.** Localization of main peptidergic systems in mammalian retina.

	MOUSE	RAT	GUINEA PIG	RABBIT	CAT	PIG	PRIMATE
Tachykinins	AC, DAC	AC*, DAC, GC	AC, DAC	AC*, DAC, GC	AC*, DAC		AC*, DAC, GC
SRIF	AC, DAC	AC, DAC	AC, DAC	DAC	DAC, GC		AC, DAC, GC
VIP	AC	AC*	AC	AC*, DAC	AC*	AC	AC*
PACAP		AC, GC, HC					
NPY	AC, DAC	AC*, DAC	AC		AC*, GC	AC	AC*, GC
Opioids			AC				
CRF		AC, DAC					AC, DAC
CCK					AC, HC		AC, BC

AC: amacrine cells; BC: bipolar cells; DAC: displaced amacrine cells; GC: ganglion cells; HC: horizontal cells. \*: Colocalization with GABA.

particular, the  $sst_1$  receptor is predominantly expressed by SRIF-containing amacrine cells, indicating that it may function as an autoreceptor (Helboe and Moller, 1999; Cristiani et al., 2000; Dal Monte et al., 2003b). Numerous evidence indicates that SRIF mediates its actions by interacting mainly with  $sst_2$  receptors which, in the rabbit retina, couple to  $G_{\alpha}$  (Vasilaki et al., 2003). Of the two  $sst_2$  receptor isoforms,  $sst_{2A}$  receptor has been immunohistochemically localized in rat, rabbit and mouse retinas (Johnson et al., 1998, 1999; Helboe and Moller, 1999; Fontanesi et al., 2000; Petrucci et al., 2001; Vasilaki et al., 2001; Cristiani et al., 2002). In rabbits, it is expressed mainly by rod bipolar and by sparse amacrine cells. These amacrine cells have been reported to lack (Johnson et al., 1998) or only to partially express (Fontanesi et al., 2000) tyrosine hydroxylase (TH) immunoreactivity. In the rat retina,  $sst_{2A}$  receptor has been localized in amacrine cells, including TH-containing amacrine cells, in rod and cone bipolar cells and in horizontal cells (Johnson et al., 1999). The finding of  $sst_{2A}$  receptors expressed by bipolar cells is consistent with recent data demonstrating that SRIF may control the retinal release of glutamate through the activation of  $sst_2$  receptors (Dal Monte et al., 2003a). This is also consistent with previous results reporting a SRIF-induced,  $sst_2$  receptor-mediated down-regulation of  $Ca^{2+}$  influx in dissociated rod bipolar cells, thus providing evidence for an inhibitory feedback loop regulating transmitter release from rod bipolar cells (Petrucci et al., 2001). The  $sst_{2B}$  receptor isoform in the rat retina is predominantly found on the membrane of photoreceptors, indicating SRIF actions in the outer retina (Vasilaki et al., 2001). Finally,  $sst_4$  receptor immunolabeling in mouse retinas is localized to sparse cells in the GCL that originate long process bundles in the NFL. These cells cannot be observed after optic nerve transection and they are therefore interpreted as ganglion cells (Cristiani et al., 2002).

### Neuropeptide expression in developing mammalian retinas


Peptidergic systems that have been investigated with some detail in the developing mammalian retina include tachykinin peptides, SRIF, VIP, PACAP, NPY, opioid peptides and CRF.

#### Tachykinin peptides

In immunohistochemical studies, antibodies directed to SP are likely to also recognize neurokinin A and neurokinin B (Brecha et al., 1989), therefore we will refer to the reported immunolabeling as tachykinin immunoreactivity. Immunohistochemical methods have been employed to study the development of tachykinin peptide-containing cells in rabbit, rat and human retinas (Sakiyama et al., 1984; Nguyen-Legros et al., 1986; Yew et al., 1991; Zhang and Yeh, 1992; Jotwani et al., 1994; Casini et al., 1997b, 2000) and in the human

retinogeniculate pathway (Wadhwa et al., 1988). In addition, there are reports of reduction in the number of tachykinin-containing amacrine cells in a guinea pig model of experimental growth retardation (Rees and Bainbridge, 1992), while no effects are detected in the development or survival of the tachykinin-immunostained amacrine cells following neonatal optic nerve transection (Osborne and Perry, 1985). In mammalian retinas, tachykinin immunoreactivity and tachykinin mRNA have been localized to mainly amacrine and displaced amacrine cells, with their processes arborizing at three distinct levels in the IPL. In addition, the presence of tachykinin immunoreactivity in ganglion cells of the rat and rabbit retina has been documented (see Casini et al., 1997b, 2002, for references).


In rat retinas, earlier investigations reported that tachykinin immunoreactivity could be first detected in amacrine cells at PND 4 or PND 5, while displaced amacrine cells in the GCL were detected later (Sakiyama



**Fig. 3.** Tachykinin immunofluorescence micrographs in sections through the thickness of rat retinas. Immunolabeled somata are detected at birth in the inner neuroblastic layer (NBL) and in the GCL (arrows in **A**). At eye opening (**B**), the immunostaining pattern is similar to that of adult retinas. Other abbreviations as in the text. Scale bar: 40  $\mu$ m.

et al., 1984; Zhang and Yeh, 1992). More recent data, indicate that tachykinin-containing cells are already present in the newborn retina and that they are located both in the INL and in the GCL (Casini et al., 2000; Fig. 3). Interestingly, [ $^3\text{H}$ ]-thymidine experiments indicate that the tachykinin-containing cells in the INL and those in the GCL constitute two separate groups that are generated in two distinct histogenetic waves during the time frame of amacrine cell birth (Zhang and Yeh, 1992). These studies also demonstrated that the cells in the INL begin detectable expression of tachykinin peptides 6-8 days after their birth, while the lag in tachykinin expression in cells of the GCL reaches 10-12 days. Furthermore, since the number of immunostained cells both in the INL and in the GCL significantly increases over the first 3 postnatal weeks and mitotic activity is absent during this period, it can be hypothesized that several cells start the expression of the tachykinin phenotype over a relatively extended period of postnatal development (Zhang and Yeh, 1992). A similar observation has been reported in the development of dopaminergic amacrine cells of the rabbit retina (Casini and Brecha, 1992b), and it indicates two possible alternatives for the formation of amacrine cell populations characterized by a neurochemical phenotype: either (i) a number of cells are committed to a certain phenotype at the time of their birth but its expression is delayed over a long developmental period; or (ii) there are cells that are not committed but start expressing a particular phenotype under the influence of signals that become available in the microenvironment. Tachykinin peptides, presumably released by the first differentiated cells, may induce the expression or the acquisition of the same phenotype in other cells during the subsequent developmental period.

In the rabbit retina, tachykinin-immunolabeled cells



**Fig. 4.** Low power photomicrograph from a whole-mounted rabbit retina at PND 0 showing fiber bundles directed to the optic disk (asterisk) and probably representing tachykinin-immunolabeled ganglion cell axons. Scale bar: 150  $\mu\text{m}$ .

are present in the GCL of the newborn retina, while immunostained cells in the INL are seen at PND 2 (Casini et al., 1997b), following a temporal pattern that is opposed to that observed in rat retinas, where tachykinin-containing cells in the INL seem to appear before those in the GCL (Sakiyama et al., 1984; Zhang and Yeh, 1992). In adult rabbit retinas, many of the tachykinin-containing cells in the GCL are ganglion cells (Brecha et al., 1987), and many of the tachykinin-immunolabeled cells in the GCL of developing retinas are also likely to be ganglion cells. Indeed, in newborn retinas heavily immunolabeled fiber bundles can be seen to run in the NFL and to converge into the optic disk (Casini et al., 1997b; Fig. 4). Both in rat and in rabbit retinas, the morphological development of the tachykinin-containing cells in the INL as well as in the GCL is completed by the time of eye opening (see Fig. 3; Sakiyama et al., 1984; Zhang and Yeh, 1992; Casini et al., 1997b).

In human retinas, tachykinin-containing cells have been identified, together with other neuroactive substances, at embryonic ages. There are discrepancies concerning the time of the first appearance of detectable levels of tachykinin immunoreactivity in retinal cells. An earlier investigation reported the first detection of tachykinin immunoreactivity in retinas of 24-29-week-old fetuses (Nguyen-Legros et al., 1986), while a more recent paper puts it at around 14 weeks (Jotwani et al., 1994). The earliest identification of tachykinin immunoreactivity in human retinas is reported in cells of the neuroblastic layer of 10-week-old fetuses, with subsequent development characterized by the migration of these cells into the inner layers of the retina (Yew et al., 1991). In addition, the presence of tachykinin immunoreactivity in optic nerves at 13-14 weeks of gestation indicates the presence of tachykinin-expressing ganglion cells in the developing human retina (Wadhwa et al., 1988).

Together, the studies of the localization of tachykinin peptides in developing mammalian retinas indicate that these peptides are expressed at early times of retinal maturation and roughly at the same time when other neurotransmitter systems begin their expression. The subsequent maturation of the tachykinin-containing cell populations follows a pattern that is similar to that of most amacrine cells and that is almost complete at the time of eye opening. SP and/or other tachykinin peptides presumably released in the developing retina may play a developmental role; however, it is difficult to hypothesize what kind of actions are performed by tachykinin peptides in developing retinas and whether these actions can be distinguished from those of other neuroactive substances that are present in the retina at the same time. An analysis of the expression of the neurokinin receptors in developing retinas may help to shed some light onto certain characteristics of the physiological actions of tachykinin peptides during retinal development.

Of the three neurokinin receptors, NK1 and NK3 are

*Peptides in retinal development*


present in the adult as well as in the developing rat retina, while NK2 is absent (Oyamada et al., 1999). The main finding about the developmental expression of NK1 and NK3 receptors in the rat retina is that NK1 receptors are expressed at early postnatal ages, while NK3 receptors appear only near the time of eye opening (Oyamada et al., 1999; Casini et al., 2000; Fig. 5), when the main morphological and functional characteristics of the retinal pathways have reached their maturity. These observations strongly suggest that SP may act at its preferred receptor (the NK1 receptor) in the retina during the whole period of postnatal development and therefore it may be implicated in developmental functions. In contrast, neurokinin B (the preferred ligand of NK3 receptors) could begin interactions with its receptors only when the retinal circuitry is almost ready to start the processing of visual stimuli, and developmental functions of neurokinin B and NK3 receptors seem unlikely.

In particular, NK1 receptors are expressed in the newborn retina by presumed ganglion cells and by a few amacrine cells in the neuroblastic layer. The subsequent development is characterized by substantial rearrangements of the NK1 expression patterns, which include an increase in the number of NK1-immunopositive amacrine cells, concomitant with a decrease in the number of immunolabeled presumed ganglion cells, and changes in the laminar distribution of NK1-immunostained fibers in the IPL. These fibers are first distributed to laminae 1, 3 and 5 of the IPL from

PND 0 to PND 7, then they change to a pattern, seen at PND 12, where the most intensely immunolabeled part of the IPL is lamina 2, as in mature retinas (Casini et al., 2000). These findings, indicating profound changes in the expression patterns of NK1 receptors during retinal development, suggest that SP and NK1 receptors may mediate processes in the developing retina that are different from those in the retina capable of visual information processing.

NK3 receptors in adult rat and mouse retinas are expressed by populations of OFF-type cone bipolar cells (Oyamada et al., 1999; Casini et al., 2000; Haverkamp et al., 2003) and in dopaminergic amacrine cells (Chen et al., 2000). The same bipolar cells that express NK3 receptors can also be labeled with antibodies directed to the calcium binding protein recoverin (Casini et al., 2000; Haverkamp et al., 2003). A parallel immunohistochemical investigation of NK3 and recoverin immunolabelings in the developing rat retina indicated that recoverin-containing bipolar cells have reached an advanced degree of morphological maturation when they start expressing NK3 receptors, at a time just before eye opening (Casini et al., 2000; Fig. 5). This observation suggests that the timing of NK3 receptor expression is set to allow certain types of bipolar cells to initiate their functions in visual information processing, and that NK3 expression in these cells is not required for developmental functions.

Recent immunohistochemical investigations on the expression of NK1 receptors in developing rabbit retinas



**Fig. 5.** Immunofluorescence micrographs in sections through the thickness of rat retinas at early postnatal ages (A-C) and at eye opening (D-F). **A and D** are NK1-immunostained sections; **B and E** are NK3-immunostained sections; **C and F** are recoverin-immunostained sections. NK1 receptors are expressed early in the retina (**A**), while NK3 receptors are first observed near eye opening (**E**). Recoverin-immunolabeled bipolar cells are visible in the retina (**C**) when NK3 immunoreactivity is still undetectable. Refer to the text for further explanation. Scale bar: 40  $\mu$ m.

seem to allow exciting new hypotheses on possible roles played by SP in the developing retina. As reported above, NK1 receptors in mature rabbit retinas are expressed by a population of ON-type cone bipolar cells and by the population of dopaminergic amacrine cells identified by tyrosine hydroxylase immunoreactivity (Casini et al., 2002). This adult pattern is achieved around the time of eye opening after a drastic rearrangement during the postnatal developmental period. In particular, before eye opening, NK1 receptors are expressed by cholinergic amacrine cells, while NK1 expression in dopaminergic amacrine cells and in bipolar cells is detected only at later ages (Casini et al., submitted; Fig. 6). Consistent with these immunocytochemical data, SP is ineffective in stimulating DA release in the developing retina, while it stimulates DA release in the mature retina (Casini et al., submitted). It is easy to hypothesize that this surprising switch in NK1 expression patterns may reflect substantial changes in the functional actions of SP. In particular, the onset of NK1 expression in dopaminergic amacrine cells and in a population of ON-type cone bipolar cells at eye opening indicates that this pattern is consistent with actions played by SP on vertical retinal pathways and on dopaminergic amacrine cells for visual information processing, probably including modulation of light adaptation (see Casini et al., 2002). In contrast, the expression of NK1 receptors by cholinergic amacrine cells in the immature retina is likely to be related to a role of SP in modulating cholinergic neurotransmission in the developing retina. Since cholinergic amacrine


cells have been shown to directly participate in the spontaneous rhythmic activities in the developing rabbit retina (Zhou, 2001b; Feller, 2002), SP may be a factor implicated in the regulation of this important mechanism. Consistent with this hypothesis, SP or a SP agonist have been observed to increase the intracellular  $Ca^{2+}$  levels in individual cholinergic amacrine cells of the newborn rabbit retina (Casini et al., submitted).

### Somatostatin

As mentioned above, SRIF-14 is the predominant form of SRIF in most mammalian retinas. In adult retinas, SRIF immunoreactivity is localized to sparsely distributed, wide-field amacrine and displaced amacrine cells in the rat, guinea pig and human. In the rabbit, cat and primate retina, most SRIF immunoreactive cells are displaced amacrine cells, and they are predominantly distributed to ventral retinal regions. SRIF immunoreactivity has also been localized in a small percentage of ganglion cells in cat and monkey retinas (see Cristiani et al., 2002, for references).

The development of SRIF-containing cells has been investigated in a variety of mammalian retinas, including rat (Kirsch and Leonhardt, 1979; Ferriero and Sagar, 1987; Ferriero et al., 1990), rabbit (Brecha et al., 1991), guinea pig (Spira et al., 1984), and cat (Mitrofanis et al., 1989b; White and Chalupa, 1992). In human retinas there are also observations of the presence of SRIF-containing cells, mainly in the GCL on the 14<sup>th</sup> or 15<sup>th</sup> week of gestation (Mitrofanis et al., 1989b; Jen et al., 1994), with immunolabeled cells that are first observed in the central retina and which subsequently become restricted to ventral retinal regions (Mitrofanis et al., 1989b).

In rat retinas, the first SRIF immunoreactive cells appear in the neuroblastic layer as early as embryonic day 16 (Ferriero and Sagar, 1987). These cells are migrating neuroblasts that reach the GCL where they are homogeneously distributed at embryonic day 20. At birth, SRIF-containing cells are only localized in the GCL, while from PND 4 to PND 10 the number of immunostained cells increases in the INL and decreases in the GCL. During the same period, the processes of these cells grow into the IPL (Ferriero and Sagar, 1987). Radioimmunoassay studies show that SRIF is present in a very high concentration prenatally (10-fold higher concentration than in adults), while SRIF levels dramatically decrease soon after birth, and at PND 4 they amount to 14% of adult values. Subsequently, there is an increase until, by the time of eye opening, the amount of SRIF approaches adult levels (Ferriero and Sagar, 1987). A similar developmental pattern has been described for SRIF mRNA, suggesting that SRIF gene expression is controlled throughout development at the transcriptional level (Ferriero et al., 1990). Interestingly, the content of SRIF-28, which is virtually absent in adult retinas, is similar to that of SRIF-14 from embryonic day 19 to approximately PND 4, then it declines



**Fig. 6.** Developmental expression of NK1 receptors in the rabbit retina as described in the text. Red indicates tyrosine hydroxylase immunoreactivity; blue indicates choline acetyltransferase immunoreactivity; green indicates NK1 receptors.

considerably around eye opening time (Ferriero et al., 1990). These observations, indicating high levels of SRIF-14, SRIF-28 and SRIF mRNA at late prenatal/early postnatal periods strongly suggest a role of somatostatinergic transmission in retinal development.

In rabbit retinas, SRIF immunolabeled cells are first observed at embryonic day 25, which is about five days before birth, in small somata scattered throughout the INL of the ventral retina. These cells progressively migrate to the GCL, where they are exclusively localized at PND 4. SRIF immunoreactive processes invade specific IPL laminae to reach the adult pattern at eye opening (Brecha et al., 1991). An additional population of SRIF-containing cells, different from that of sparsely distributed displaced amacrine cells, is transiently present in the GCL from embryonic day 29 to PND 15-20. These cells are confined to the ventral retina and they are characterized by a lack of any immunostained processes. They are distributed in an apparently regular array with peak density in the central retina and lower density in the peripheral retina (Brecha et al., 1991). Although the significance of this transient population of SRIF-containing cells is unknown, their regular array indicates that they may serve as stable positional markers which may influence the direction of fiber outgrowth in the developing retina and/or the development of retinal mosaics.

In guinea pig retinas, different from other species, the predominant form of SRIF is SRIF-28. SRIF immunoreactive somata are only localized in far peripheral retinal regions in the INL, IPL and GCL, with fibers in the IPL and in the NFL. In addition, the observation of immunostained fibers in the optic nerve and disc suggests the presence of SRIF-containing ganglion cells (Spira et al., 1984). SRIF quantified by radioimmunoassay is detected as early as the 6<sup>th</sup> week of gestation (full term is 10 weeks). Immunohistochemically-detected SRIF-containing cells are seen at 2 weeks before birth, coincident with the period of the most rapid increase in SRIF levels determined with radioimmunoassay. At birth, SRIF levels amount to two-thirds of adult levels (Spira et al., 1984).

In adult cat retinas, SRIF-containing cells are represented by displaced amacrine and alpha ganglion cells that are mainly distributed to the ventral retina (White and Chalupa, 1991). During development, SRIF immunoreactivity is first detected at embryonic day 30 in cells located in the innermost part of the retina. These cells belong to the population of displaced amacrine cells. They are first located in central retinal regions, but soon their pattern of distribution undergoes a substantial remodeling and at embryonic day 38 these SRIF-immunoreactive cells are detected in retinal peripheral areas. At embryonic day 45, SRIF-containing displaced amacrine cells are located principally in the inferior half of the retina, as in adults (White and Chalupa, 1992). No further significant changes in this cell population are observed throughout postnatal development (Mitrofanis

et al., 1989b; White and Chalupa, 1992). The first SRIF-immunostained alpha ganglion cells are detected at PND 5. From their earliest appearance, these cells are located principally in the inferior retina. Their number gradually increases over an extended period of postnatal development, and at PND 38 they are still 40-70% of the adult population. The postnatal period is also characterized by the development of a rich meshwork of SRIF-immunolabeled processes that extend in laminae 1, 3 and 5 of the IPL in all retinal regions (White and Chalupa, 1992).

Together, these studies indicate that in all mammalian retinas SRIF is expressed at early developmental times. In addition, in specific mammalian retinas there are marked changes in SRIF content, in the levels of expression of SRIF mRNA, in the presence of specific SRIF-containing cell populations or in the distribution patterns of SRIF-immunoreactive amacrine cells. However, the most intriguing characteristic of the development of the retinal somatostatinergic systems is perhaps the transient appearance of SRIF-containing ganglion cells which has been documented in rat (Fontanesi et al., 1997; Xiang et al., 2001) and cat (Mitrofanis et al., 1989b; White and Chalupa, 1992) retinas and which has been postulated in human retinas (Mitrofanis et al., 1989b). In the developing rat retina, most cells in the GCL express SRIF mRNA between embryonic days 13 and 21 (birth). The number of these cells rapidly decreases after birth until PND 20, when the distribution of SRIF mRNA-expressing cells in the GCL is similar to that of adults. Many, if not all, of these cells are ganglion cells, since SRIF immunoreactivity is observed in the optic chiasm, optic tract and lateral geniculate nucleus during the prenatal period (Xiang et al., 2001). Another period of transient expression of SRIF in ganglion cells of the rat retina has been identified between PND 7 and PND 14 (Fontanesi et al., 1997). A population of transient SRIF-immunoreactive ganglion cells has also been reported in the cat retina during prenatal and early postnatal development in the superior and inferior retina (Mitrofanis et al., 1989b; White and Chalupa, 1992). These cells were no longer detected at PND 38 (White and Chalupa, 1992). The disappearance of SRIF-expressing ganglion cells could be attributed to cell death that is normally present both in rat (Potts et al., 1982; Perry et al., 1983) and in cat (Williams et al., 1986) retinas during the early postnatal period. Alternatively, these cells may cease SRIF expression or reduce it to undetectable levels. The latter seems to be the most likely possibility to explain the disappearance of SRIF-containing ganglion cells in rat retinas after PND 14 (Fontanesi et al., 1997), which is after the period of maximum ganglion cell death (Potts et al., 1982; Perry et al., 1983). Whatever the causes of the transient presence of these ganglion cells, it is easy to hypothesize that SRIF expressed in these cells may play a role in the organization of the GCL and/or in the formation of retinofugal projections. For instance, in the rat retina the numerous SRIF mRNA-expressing

ganglion cells observed prenatally (Xiang et al., 2001) may influence the early outgrowth of ganglion cell projections, while the presence of SRIF-containing ganglion cells between PND 7 and PND 14 coincides with the time when mature retino-collicular projections are established (O'Leary et al., 1986) which is just before the time of maturation of retino-collicular synapses (Simon and O'Leary, 1992).


SRIF binding sites indicating the presence of functional somatostatin receptors are detected in the rat retina as early as embryonic day 15 (Ferriero, 1992) or 16 (Bodenant et al., 1991). Subsequently, their levels decrease considerably (Bodenant et al., 1991; Ferriero, 1992) to a minimum detected at PND 2 followed by a peak at PND 11 and by the achievement of adult levels at eye opening (Ferriero, 1992). These data show that the developmental pattern of SRIF receptor expression is coincident with that of SRIF mRNA and SRIF peptide.

Recent RT-PCR analysis of the developing mouse retina indicates that SRIF and all of its receptor mRNAs are expressed at birth (Fig. 7). In particular, at all postnatal ages, the levels of *sst*<sub>2</sub> mRNA are higher than those of *sst*<sub>1</sub> and similar to those of *sst*<sub>4</sub>. In addition, the developmental patterns of SRIF and *sst*<sub>2</sub> mRNAs share some similarities, with a decrease in the first postnatal week followed by a moderate increase to adult levels


around the time of eye opening (Bagnoli P., unpublished observations). Immunocytochemically identified *sst*<sub>1</sub> receptors are detected in SRIF-containing displaced amacrine cells in the early postnatal retina (Bagnoli P., unpublished observations), indicating that, as in the adult retina (Cristiani et al., 2000), they may function as autoreceptors and control early SRIF release. Recent immunohistochemical studies have investigated the pattern of *sst*<sub>2A</sub> receptor expression in the postnatal rabbit retina (Fontanesi et al., 2000). These receptors are present at birth and throughout postnatal development and they are localized in horizontal cells, rod bipolar cells and amacrine cells including TH immunoreactive amacrine cells, as in adult retinas. The adult pattern is reached at eye opening (Fontanesi et al., 2000). In the mouse retina, *sst*<sub>2A</sub> expression by dopaminergic amacrine cells seems to precede that by rod bipolar cells (Bagnoli and Dal Monte unpublished observation).

The postnatal development of retinas of mice carrying genetic deletion of single SRIF receptors are under investigation by our group. Recent findings demonstrate major compensatory mechanisms induced by the deletion of *sst*<sub>1</sub> receptors (Dal Monte et al., 2003b). In particular, there is an increase in the levels of both SRIF and *sst*<sub>2</sub> receptor mRNA, indicating that *sst*<sub>1</sub> receptors may be involved in the regulation of both SRIF and *sst*<sub>2</sub> receptor expression. In addition, the increase of *sst*<sub>2</sub> receptor mRNA expression is accompanied by an increased expression of the *sst*<sub>2A</sub> receptor isoform in rod bipolar cell axonal terminals, which is correlated with an increased size of rod bipolar cell axonal endings. These observations indicate that rod bipolar cell morphogenesis is affected by the deletion of the *sst*<sub>1</sub> receptor.

### Birth



### Adult



**Fig. 7.** Semiquantitative RT-PCR analysis of the expression of SRIF and its receptors in the newborn and in the adult mouse retina. Cyclophilin B mRNA was used as internal standard. All SRIF receptors are present, although in different amounts.

### Vasoactive intestinal polypeptide

In mammalian retinas, VIP is localized in a population of wide-field amacrine cells and in a few displaced amacrine cells (see Lee et al., 2002, for references) which, in the rabbit retina, have been shown to constitute a subpopulation of GABAergic amacrine cells (Casini and Brecha, 1992c).

The development of VIP-containing amacrine cells has been investigated in rat retinas. In an earlier immunocytochemical study, VIP-immunoreactive amacrine cells were first observed at PND 12, which is 2–3 days before eye opening (Terubayashi et al., 1982). However it seems likely that VIP expression in the rat retina appears within a few days after birth. Indeed, VIP immunoreactivity was detected in retinal cell cultures within 6 days after plating dissociated retinal cells from rats at embryonic day 19 (Fukuda et al., 1987), suggesting that, if developmental times in culture are similar to those *in vivo*, VIP-containing cells should appear around PND 5. More recent *in situ* hybridization studies confirmed that VIP mRNA is expressed in rat retinas at PND 5 (Casini et al., 1994). These cells appear to complete the migration to their final laminar position in the INL and in the GCL by the time of eye opening. In

## Peptides in retinal development

addition, VIP-expressing amacrine cells are distributed in a fairly regular mosaic just before eye opening, suggesting they may efficiently influence all retinal regions at this time. A quantitative analysis of the VIP mRNA-expressing amacrine cells in postnatal rat retinas indicated that both cell density (labeled cells/mm<sup>2</sup> of retinal area) and total cell number peak at PND 15 (eye opening) and decrease to adult values in the following period (Casini et al., 1994). The increase in VIP mRNA-expressing cells is unlikely to be due to the addition of new cells, since mitotic activity in the rat retina ceases by PND 8 (Webster and Rowe, 1991), while the decrease in labeled cells after PND 15 cannot be ascribed to cell death among amacrine cells, since it has virtually ceased by PND 13 (Horsburgh and Sefton, 1987). It therefore appears that some amacrine cells may transiently express VIP during the time of eye opening. These observations suggest that VIP could act as an important factor during a specific period of retinal development when retinal pathways begin the processing of visual information. Other studies show that in retinal cell cultures derived from early postnatal rats, VIP protects retinal neurons from tetrodotoxin-induced death or from glutamate neurotoxicity, probably by stimulating cAMP production (Kaiser and Lipton, 1990; Shoge et al., 1998), indicating that VIP may behave as a growth or protecting factor for retinal cells in the developing retina. In addition, VIP possibly released by the retina and the choroid promotes the differentiation of a functional retinal pigment epithelium during development (Koh, 2000). Finally, studies in juvenile monkeys which had developed myopia after lid fusion due to excessive elongation of the eye reported that VIP immunohistochemical staining was much stronger in the closed than in the open eyes (Stone et al., 1988), suggesting that VIP may play a part in the regulation of postnatal ocular growth.

Together, these studies indicate potential roles of VIP in a variety of aspects of the development of the retina and of other ocular tissues, although specific actions exerted by this peptide have yet to be clarified.

### *Pituitary adenylate cyclase activating polypeptide*

Only a few studies have investigated the presence of PACAP in developing retinas, but the findings indicate that it is expressed early in development. For instance, PACAP mRNA has been detected in the GCL of rat retinas at embryonic day 20 (Skoglosa et al., 1999), while RT-PCR and receptor-binding studies have reported the presence of PACAP and of PAC1, VPAC1 and VPAC2 receptors in retinas of 12-18-week human embryos (Olianas et al., 1997).

Similar to VIP, PACAP protects retinal neurons from cell death. In particular, administration of PACAP to retinal cell cultures from early postnatal rats increases the survival of different types of retinal cells counteracting anisomycin- or glutamate-induced cell death (Shoge et al., 1999; Silveira et al., 2002). In addition, it is demonstrated that the protective actions

are mediated by PAC1 receptors through the intracellular cAMP/cAMP-dependent protein kinase pathway (Silveira et al., 2002). These findings indicate that PACAP may represent an important factor modulating cell death/survival in the developing retina.


### *Neuropeptide Y*

In mammalian retinas, NPY immunoreactivity is localized in wide-field amacrine and displaced amacrine cells. In addition, it is also reported in ganglion cells of the cat and human retina (see Oh et al., 2002, for references).

In the human fetal retina, NPY immunopositive cells have been found as early as 14 or 15 weeks gestation in the INL (Jen et al., 1994; Jotwani et al., 1994), while by 17 weeks gestation, NPY-containing cells are also observed in the GCL (Jen et al., 1994).

In mouse retinas, RT-PCR data show that NPY expression does not vary between PND 7 and PND 17, while the expression of NPY receptor subtypes Y1 and Y2 increases from PND 7 to PND 12. Studies in a mouse model of oxygen-induced retinopathy suggest that NPY is involved in abnormal angiogenesis in retinopathy (Yoon et al., 2002).

In rat retinas, there are immunocytochemical observations showing that NPY-containing cells appear in the GCL at late prenatal ages. At PND 6, the first immunolabeled cells are observed in the INL and by PND 13, NPY-containing cell populations in the INL and in the GCL can be appreciated (Ferriero and Sagar, 1989). Radioimmunoassay measurements of NPY indicated a transient increase in NPY expression around PND 13, which is near eye opening (Ferriero and Sagar, 1989). A similar developmental pattern is found in mouse retinas, where a peak of NPY mRNA is recorded with semi-quantitative RT-PCR analysis at the time of



**Fig. 8.** Time course of NPY mRNA expression in the mouse retina as determined with RT-PCR semiquantitative analysis using cyclophilin B mRNA as internal standard. A significant, transient increase in NPY mRNA levels is observed at the time of eye opening ( $P < 0.01$ ).

eye opening (Bagnoli and Dal Monte unpublished observations; Fig. 8). The transient increase in NPY expression at eye opening suggests that this peptide may have a role at this time in modulating developing retinal circuitry.

In cat retinas, NPY-immunoreactive cells are first observed at embryonic day 46 in the GCL, while by embryonic day 50 they are also observed in the INL. Both the amacrine cell population in the INL and the ganglion cell group in the GCL (identified by retrograde labeling) initially follow a central to peripheral pattern of development. At PND 7 the number of amacrine cells approaches adult values, while the ganglion cell population shows a protracted development, with new cells being added until the third postnatal week. NPY-containing amacrine cells are regularly distributed throughout development, suggesting that they may participate in establishing the ganglion cell mosaics that appear during postnatal development (Hutsler and Chalupa, 1995).

Together, these data indicate that NPY is expressed in mammalian retinas roughly at the same time as other peptides and classical transmitters. Certain features of the NPY patterns in developing retinas may indicate some developmental roles for this peptide, however precise functions of NPY in retinal development are still unexplored.

#### *Opioid peptides*

Among mammalian retinas, opioid peptides, namely enkephalin peptides, have only been reported in guinea pig retinas, while  $\mu$  receptors are likely to be expressed by rat and monkey ganglion cells (Wamsley et al., 1981; Altschuler et al., 1982).

In human retinas, enkephalin immunoreactivity is first observed at 16 or 17 weeks gestation (Yew et al., 1991; Jotwani et al., 1994). The following development occurs in a sequence from outer to inner layers of the developing retina (Yew et al., 1991).

Some papers in the nineties investigated both the localization and the growth factor function of enkephalin peptides in the developing rat retina (Isayama and Zagon, 1991; Isayama et al., 1991, 1995, 1996). Using immunocytochemistry, in situ hybridization, Northern blot, HPLC, and receptor binding, these studies reported the expression of [Met<sup>5</sup>]-enkephalin, preproenkephalin (PPE) mRNA and [Met<sup>5</sup>]-enkephalin binding sites in late prenatal/early postnatal rat retinas. In particular, [Met<sup>5</sup>]-enkephalin-immunopositive and PPE mRNA-expressing cells are located in the neuroblastic layer and in the GCL of perinatal retinas. Immunolabeling and receptor binding are absent at PND 5-6 and in adult retinas, suggesting transient expression of [Met<sup>5</sup>]-enkephalin and its receptor (Isayama et al., 1991, 1995), although PPE mRNA has also been localized in the INL of adult rat retinas (Isayama et al., 1996).

Regarding possible functional actions of [Met<sup>5</sup>]-enkephalin in developing retinas, it is reported that this

peptide significantly reduces the proportion of cells incorporating [<sup>3</sup>H]-thymidine in PND 1 rat retinas. This effect is inhibited by the opioid antagonist naloxone, while the other antagonist naltrexone is capable of increasing [<sup>3</sup>H]-thymidine incorporation (Isayama et al., 1991). These observations indicate that opioid peptides may serve during retinal development as negative regulators of cell proliferation.

#### *Corticotropin releasing factor*

In mammalian retinas, CRF immunoreactivity is localized in wide-field amacrine and displaced amacrine cells (Marshak, 1989; Yeh and Olschowka, 1989).

CRF-immunolabeled cells are detected in rat retinas at PND 3 located in the neuroblastic layer and in the GCL. They are first distributed in central retinal regions, then they are localized to other parts of the retina following a center-to-periphery pattern of expression, with progressive growth of immunolabeled processes into specific IPL laminae. The adult distribution is achieved at PND 13 (Zhang et al., 1990). The observation that CRF-containing cells in the INL decrease in number, while those in the GCL increase during postnatal development indicates that the final distribution in the INL and in the GCL is reached by virtue of a secondary migration of CRF-containing cells from INL to GCL (Zhang et al., 1990). Further studies using [<sup>3</sup>H]-thymidine autoradiography showed that CRF-containing cells are generated between embryonic day 16-20, indicating a certain delay in the subsequent acquisition of the transmitter phenotype by these cells (Zhang and Yeh, 1991).

There are observations of transient changes in CRF expression indicating a possible importance of CRF during retinal development. Indeed, radioimmunoassay experiments suggest the presence of a peak in the expression of CRF in the retina around the time of eye opening (PND 15) (Zhang et al., 1990), which evokes the peaks in VIP and in NPY expression at the same time. In addition, immunohistochemistry combined with [<sup>3</sup>H]-thymidine autoradiography indicates the presence of transient CRF horizontal cells that are generated at embryonic day 14-18. These cells, located in the distal neuroblastic layer/INL, decrease in number around PND 7-9 following a centro-peripheral pattern and they are no longer detected at PND 19 (Zhang and Yeh, 1991).

#### **Concluding remarks**

The mammalian retina represent a useful experimental model to investigate the characteristics of neuronal development and the factors that may be implicated in such processes. The ultimate aim of these research lines is to identify selected molecules that may be employed as therapeutic agents to treat damage and/or illness of the nervous system. Although major progress has been made in the field of neuropeptides, with identification and cloning of peptide receptors,

development of peptide-related drugs and production of transgenic animals, we are still very far from a knowledge of peptide functions in neuronal development that could allow the design of peptide-based therapeutic strategies. Nonetheless, the data reviewed in the present paper indicate that after a phase in which peptides and their receptors have been localized in developing retinas, some functional properties of peptides that may affect the development of retinal neurons are beginning to be clarified and that specific aspects of the development of peptidergic systems may start attracting attention for deeper investigation. For instance, the study of possible actions of SP for the modulation of cholinergic neurotransmission sustaining the retinal spontaneous waves of activity may lead to important discoveries concerning the involvement of tachykinin peptides in the formation of intraretinal pathways and of retinofugal projections. In addition, some aspects of the developmental patterns of the somatostatinergic system, including early SRIF expression, the presence of transient SRIF-expressing ganglion cells and observations in SRIF receptor knock-out mice, clearly indicate varied roles of this peptide in retinal development that deserve detailed investigations. Furthermore, the protective and growth-promoting actions of VIP and PACAP indicate that these peptides may act to sustain retinal neurons during their development. Finally, future investigations should also concentrate on the data showing a peak in the expression of certain peptides, including VIP, NPY and CRF, around the time of eye opening, when the retinal pathways achieve their final organization and start the analysis of structured visual information, suggesting that these peptides may operate, or co-operate, during this delicate phase of retinal development.

In summary, although the story of neuropeptides reveals itself to be much more complicated than it was thought when these neuroactive molecules were first identified, the results of the research done in the developing retina as well as in other models of the developing nervous system allow a certain degree of optimism for important achievements in the field of neuropeptides in the near future.

---

*Acknowledgements.* This work was supported by the Italian Board of Education (F06/PB/RS40%) and the European Community (QLG3-1999-00908).

---

## References

- Akopian A., Johnson J., Gabriel R., Brecha N. and Witkovsky P. (2000). Somatostatin modulates voltage-gated K<sup>(+)</sup> and Ca<sup>(2+)</sup> currents in rod and cone photoreceptors of the salamander retina. *J. Neurosci.* 20, 929-936.
- Altschuler R.A., Mosinger J.L., Hoffman D.W. and Parakkal M.H. (1982). Immunocytochemical localization of enkephalin-like immunoreactivity in the retina of the guinea pig. *Proc. Natl. Acad. Sci. USA.* 79, 2398-2400.
- Bai W.Z., Meguro R., Kaiya T. and Norita M. (2001). Postnatal development of the retinal projection to the nucleus of the optic tract and accessory optic nuclei in the hooded rat. *Arch. Histol. Cytol.* 64, 69-79.
- Bishop G.A. (2002). Development of a corticotropin-releasing factor-mediated effect on the firing rate of Purkinje cells in the postnatal mouse cerebellum. *Exp. Neurol.* 178, 165-174.
- Blanks J.C., Adinolfi A.M. and Lolley R.N. (1974). Synaptogenesis in the photoreceptor terminal of the mouse retina. *J. Comp. Neurol.* 156, 81-93.
- Bloomfield S.A. and Dacheux R.F. (2001). Rod vision: pathways and processing in the mammalian retina. *Prog. Retin. Eye Res.* 20, 351-384.
- Bodenant C., Leroux P., Gonzalez B.J. and Vaudry H. (1991). Transient expression of somatostatin receptors in the rat visual system during development. *Neuroscience* 41, 595-606.
- Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J. and Guillemin R. (1973). Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. *Science* 179, 77-79.
- Brecha N., Johnson D., Bolz J., Sharma S., Parnavelas J.G. and Lieberman A.R. (1987). Substance P-immunoreactive retinal ganglion cells and their central axon terminals in the rabbit. *Nature* 327, 155-158.
- Brecha N., Johnson D., Peichl L. and Wässle H. (1988). Cholinergic amacrine cells of the rabbit retina contain glutamate decarboxylase and gamma-aminobutyrate immunoreactivity. *Proc. Natl. Acad. Sci. USA* 85, 6187-6191.
- Brecha N.C., Sternini C., Anderson K. and Krause J.E. (1989). Expression and cellular localization of substance P/neurokinin A and neurokinin B mRNAs in the rat retina. *Vis. Neurosci.* 3, 527-535.
- Brecha N.C., Casini G. and Rickman D.W. (1991). Organization and development of sparsely distributed wide-field amacrine cells in the rabbit retina. In: *The changing visual system: Maturation and aging in the central nervous system.* Bagnoli P. and Hodos W. (eds). Plenum Press. London. pp 95-117.
- Brenneman D.E. and Eiden L.E. (1986). Vasoactive intestinal peptide and electrical activity influence neuronal survival. *Proc. Natl. Acad. Sci. USA* 83, 1159-1162.
- Brenneman D.E., Eiden L.E. and Siegel R.E. (1985). Neurotrophic action of VIP on spinal cord cultures. *Peptides* 6 Suppl. 2, 35-39.
- Bruun A. and Ehinger B. (1993). NPY-induced neurotransmitter release from the rabbit and chicken retina. *Acta Ophthalmol. (Copenh.)* 71, 590-596.
- Bruun A., Edvinsson L. and Ehinger B. (1994). Neuropeptide Y inhibits adenylyl cyclase activity in rabbit retina. *Acta Ophthalmol. (Copenh.)* 72, 326-331.
- Bulloch G.M.A. (1987). Somatostatin enhances neurite outgrowth and electrical coupling of regenerating neurons in *Helisoma*. *Brain Res.* 412, 6-17.
- Burazin T.C., Larm J.A., Ryan M.C. and Gundlach A.L. (2000). Galanin-R1 and -R2 receptor mRNA expression during the development of rat brain suggests differential subtype involvement in synaptic transmission and plasticity. *Eur. J. Neurosci.* 12, 2901-2917.
- Cajal S.R. (1893). La rétine des vertébrés. *La Célule* 9, 119-257.
- Camargo De Moura Campos L. and Hokoc J.N. (1999). Ontogeny of cholinergic amacrine cells in the opossum (*Didelphis aurita*) retina. *Int. J. Dev. Neurosci.* 17, 795-804.
- Caruso D.M., Owczarzak M.T. and Pourcho R.G. (1990). Colocalization

- of substance P and GABA in retinal ganglion cells: a computer-assisted visualization. *Vis. Neurosci.* 5, 389-394.
- Casini G. and Brecha N.C. (1992a). Postnatal development of tyrosine hydroxylase immunoreactive amacrine cells in the rabbit retina: I. Morphological characterization. *J. Comp. Neurol.* 326, 283-301.
- Casini G. and Brecha N.C. (1992b). Postnatal development of tyrosine hydroxylase immunoreactive amacrine cells in the rabbit retina: II. Quantitative analysis. *J. Comp. Neurol.* 326, 302-313.
- Casini G. and Brecha N.C. (1992c). Colocalization of vasoactive intestinal polypeptide and GABA immunoreactivities in a population of wide-field amacrine cells in the rabbit retina. *Vis. Neurosci.* 8, 373-378.
- Casini G., Molnar M. and Brecha N.C. (1994). Vasoactive intestinal polypeptide/peptide histidine isoleucine messenger RNA in the rat retina: adult distribution and developmental expression. *Neuroscience* 58, 657-667.
- Casini G., Grassi A., Trasarti L. and Bagnoli P. (1996). Developmental expression of protein kinase C immunoreactivity in rod bipolar cells of the rabbit retina. *Vis. Neurosci.* 13, 817-831.
- Casini G., Rickman D.W., Sternini C. and Brecha N.C. (1997a). Neurokinin 1 receptor expression in the rat retina. *J. Comp. Neurol.* 389, 496-507.
- Casini G., Trasarti L., Andolfi L. and Bagnoli P. (1997b). Morphologic maturation of tachykinin peptide-expressing cells in the postnatal rabbit retina. *Brain Res. Dev. Brain Res.* 99, 131-141.
- Casini G., Rickman D.W., Trasarti L. and Brecha N.C. (1998). Postnatal development of parvalbumin immunoreactive amacrine cells in the rabbit retina. *Dev. Brain Res.* 111, 107-117.
- Casini G., Brecha N.C., Bosco L. and Rickman D.W. (2000). Developmental expression of neurokinin-1 and neurokinin-3 receptors in the rat retina. *J. Comp. Neurol.* 421, 275-287.
- Casini G., Sabatini A., Catalani E., Willems D., Bosco L. and Brecha N.C. (2002). Expression of the neurokinin 1 receptor in the rabbit retina. *Neuroscience* 115, 1309-1321.
- Casini G., Dal Monte M., Fornai F., Yang Q., Zhou Z.J., Bosco L. and Bagnoli P. Neurokinin 1 receptors are expressed by different cell populations and substance P plays different actions in the immature and in the mature retina. *J. Neurosci.* (submitted).
- Chen L.W., Wei L.C., Liu H.L., Duan L., Ju G. and Chan Y.S. (2000). Retinal dopaminergic neurons (A17) expressing neuromedin K receptor (NK(3)): a double immunocytochemical study in the rat. *Brain Res.* 885, 122-127.
- Colas B., Valencia A.M., Prieto J.C. and Arilla E. (1992). Somatostatin binding and modulation of adenylate cyclase in ovine retina membranes. *Mol. Cell. Endocrinol.* 88, 111-117.
- Cook J.E. and Chalupa L.M. (2000). Retinal mosaics: new insights into an old concept. *Trends Neurosci.* 23, 26-34.
- Cristiani R., Fontanesi G., Casini G., Petrucci C., Viollet C. and Bagnoli P. (2000). Expression of somatostatin subtype 1 receptor in the rabbit retina. *Invest. Ophthalmol. Vis. Sci.* 41, 3191-3199.
- Cristiani R., Petrucci C., Dal Monte M. and Bagnoli P. (2002). Somatostatin (SRIF) and SRIF receptors in the mouse retina. *Brain Res.* 936, 1-14.
- Croiset G., Nijsen M.J. and Kamphuis P.J. (2000). Role of corticotropin-releasing factor, vasopressin and the autonomic nervous system in learning and memory. *Eur. J. Pharmacol.* 405, 225-234.
- Csaba Z. and Dournaud P. (2001). Cellular biology of somatostatin receptors. *Neuropeptides* 35, 1-23.
- Cuenca N. and Kolb H. (1998). Circuitry and role of substance P-immunoreactive neurons in the primate retina. *J. Comp. Neurol.* 393, 439-456.
- Dal Monte M., Petrucci C., Cozzi A., Allen J.P. and Bagnoli P. (2003a). Somatostatin inhibits potassium-evoked glutamate release by activation of the sst2 somatostatin receptor in the mouse retina. *Naunyn Schmiedebergs Arch. Pharmacol.* 367, 188-192.
- Dal Monte M., Petrucci C., Vasilaki A., Cervia D., Grouselle D., Epelbaum J., Kreienkamp H.J., Richter D., Hoyer D. and Bagnoli P. (2003b). Genetic deletion of somatostatin receptor 1 alters somatostatinergic transmission in the mouse retina. *Neuropharmacol.* (in press).
- Danger J.M., Tonon M.C., Jenks B.G., Saint-Pierre S., Martel J.C., Fasolo A., Breton B., Quirion R., Pelletier G. and Vaudry H. (1990). Neuropeptide Y: localization in the central nervous system and neuroendocrine functions. *Fundam. Clin. Pharmacol.* 4, 307-340.
- De Felipe C., Pinnock R.D. and Hunt S.P. (1995). Modulation of chemotropism in the developing spinal cord by substance P. *Science* 267, 899-902.
- Dhingra N.K., Ramamohan Y. and Raju T.R. (1997). Developmental expression of synaptophysin, synapsin I and syntaxin in the rat retina. *Dev. Brain Res.* 102, 267-273.
- DiCicco-Bloom E., Lu N., Pintar J.E. and Zhang J. (1998). The PACAP ligand/receptor system regulates cerebral cortical neurogenesis. *Ann. N.Y. Acad. Sci.* 865, 274-289.
- DiCicco-Bloom E., Deutsch P.J., Maltzman J., Zhang J., Pintar J.E., Zheng J., Friedman W.F., Zhou X. and Zaremba T. (2000). Autocrine expression and ontogenetic functions of the PACAP ligand/receptor system during sympathetic development. *Dev. Biol.* 219, 197-213.
- Drahushuk K., Connell T.D. and Higgins D. (2002). Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide inhibit dendritic growth in cultured sympathetic neurons. *J. Neurosci.* 22, 6560-6569.
- el Azazi M. and Wachtmeister L. (1993). The postnatal development of the oscillatory potentials of the electroretinogram V. Relation to the double peaked a-wave. *Acta Ophthalmol. (Copenh)* 71, 32-38.
- Emerit M.B., Riad M. and Hamon M. (1992). Trophic effects of neurotransmitters during brain maturation. *Biol. Neonate* 62, 193-201.
- Euler T. and Wässle H. (1995). Immunocytochemical identification of cone bipolar cells in the rat retina. *J. Comp. Neurol.* 361, 461-478.
- Feigenspan A. and Bormann J. (1994). Facilitation of GABAergic signaling in the retina by receptors stimulating adenylate cyclase. *Proc. Natl. Acad. Sci. USA* 91, 10893-10897.
- Feller M.B. (2002). The role of nAChR-mediated spontaneous retinal activity in visual system development. *J. Neurobiol.* 53, 556-567.
- Feller M.B., Wellis D.P., Stellwagen D., Werblin F.S. and Shatz C.J. (1996). Requirement for cholinergic synaptic transmission in the propagation of spontaneous retinal waves. *Science* 272, 1182-1187.
- Ferriero D.M. (1992). Developmental expression of somatostatin receptors in the rat retina. *Dev. Brain Res.* 67, 309-315.
- Ferriero D.M. and Sagar S.M. (1987). Development of somatostatin immunoreactive neurons in rat retina. *Brain Res.* 431, 207-214.
- Ferriero D.M. and Sagar S.M. (1989). Development of neuropeptide Y-immunoreactive neurons in the rat retina. *Dev. Brain Res.* 48, 19-26.
- Ferriero D.M., Head V.A., Edwards R.H. and Sagar S.M. (1990). Somatostatin mRNA and molecular forms during development of the rat retina. *Dev. Brain Res.* 57, 15-19.
- Fontanesi G., Casini G., Thanos S. and Bagnoli P. (1997). Transient

*Peptides in retinal development*

- somatostatin-immunoreactive ganglion cells in the developing rat retina. *Dev. Brain Res.* 103, 119-125.
- Fontanesi G., Petrucci C., Lazzarini M., Blandizzi C., Del Tacca M. and Bagnoli P. (1998). Chronic exposure to either somatostatin (SS) or octreotide, a long-lasting SS analogue, affects SS expression in the postnatal visual cortex of the rat. *Brain Res. Dev. Brain. Res.* 107, 91-102.
- Fontanesi G., Gargini C. and Bagnoli P. (2000). Postnatal development of somatostatin 2A (sst2A) receptors expression in the rabbit retina. *Dev. Brain Res.* 123, 67-80.
- Fukuda M., Yeh H.H. and Puro D.G. (1987). A vasoactive intestinal polypeptide system in retinal cell cultures: immunocytochemistry and physiology. *Brain Res.* 414, 177-181.
- Garey L.J. (1984). Structural development of the visual system of man. *Hum. Neurobiol.* 3, 75-80.
- Gonzalez B., Leroux P., Lamacz M., Bodenat C., Balasz R. and Vaudry H. (1992). Somatostatin receptors are expressed by immature cerebellar granule cells: evidence for a direct inhibitory effect of somatostatin on neuroblast activity. *Proc. Natl. Acad. Sci. USA* 89, 9627-9631.
- Goodman C.S. and Shatz C.J. (1993). Developmental mechanisms that generate precise patterns of neuronal connectivity. *Cell* 72, 77-98.
- Gozes I. and Brenneman D.E. (2000). A new concept in the pharmacology of neuroprotection. *J. Mol. Neurosci.* 14, 61-68.
- Gozes I., Bardea A., Reshef A., Zamostiano R., Zhukovsky S., Rubinraut S., Fridkin M. and Brenneman D.E. (1996). Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. *Proc. Natl. Acad. Sci. USA.* 93, 427-432.
- Greiner J.V. and Weidman T.A. (1982). Embryogenesis of the rabbit retina. *Exp. Eye Res.* 34, 749-765.
- Greka A., Lipton S.A. and Zhang D. (2000). Expression of GABA(C) receptor rho1 and rho2 subunits during development of the mouse retina. *Eur. J. Neurosci.* 12, 3575-3582.
- Gressens P. (1998). Vasoactive intestinal peptide: a novel neurotrophic factor. *Arch. Pediatr.* 5, 654-660.
- Gressens P., Hill J.M., Gozes I., Fridkin M. and Brenneman D.E. (1993). Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. *Nature* 362, 155-158.
- Gressens P., Marret S., Hill J.M., Brenneman D.E., Gozes I., Fridkin M. and Evrard P. (1997). Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. *J. Clin. Invest.* 100, 390-397.
- Grimm-Jorgensen Y. (1987). Somatostatin and calcitonin stimulate neurite regeneration of molluscan neurons in vitro. *Brain Res.* 403, 121-126.
- Ha B.K., Bishop G.A., King J.S. and Burry R.W. (2000). Corticotropin releasing factor induces proliferation of cerebellar astrocytes. *J. Neurosci. Res.* 62, 789-798.
- Hannibal J., Moller M., Ottersen O.P. and Fahrenkrug J. (2000). PACAP and glutamate are co-stored in the retinohypothalamic tract. *J. Comp. Neurol.* 418, 147-155.
- Hannon J.P., Nunn C., Stolz B., Bruns C., Weckbecker G., Lewis I., Troxler T., Hurth K. and Hoyer D. (2002). Drug design at peptide receptors: somatostatin receptor ligands. *J. Mol. Neurosci.* 18, 15-27.
- Hansel D.E., Eipper B.A. and Ronnett G.V. (2001a). Regulation of olfactory neurogenesis by amidated neuropeptides. *J. Neurosci. Res.* 66, 1-7.
- Hansel D.E., Eipper B.A. and Ronnett G.V. (2001b). Neuropeptide Y functions as a neuroproliferative factor. *Nature* 410, 940-944.
- Harrison S. and Geppetti P. (2001). Substance p. *Int. J. Biochem. Cell. Biol.* 33, 555-576.
- Hartveit E. (1997). Functional organization of cone bipolar cells in the rat retina. *J. Neurophysiol.* 77, 1716-1730.
- Hartveit E., Brandstätter J.H., Sassoè-Pognetto M., Laurie D.J., Seeburg P.H. and Wässle H. (1994). Localization and developmental expression of the NMDA receptor subunit NR2A in the mammalian retina. *J. Comp. Neurol.* 348, 570-582.
- Hasenohrl R.U., Souza-Silva M.A., Nikolaus S., Tomaz C., Brandao M.L., Schwarting R.K. and Huston J.P. (2000). Substance P and its role in neural mechanisms governing learning, anxiety and functional recovery. *Neuropeptides* 34, 272-280.
- Hauser K.F. and Mangoura D. (1998). Diversity of the endogenous opioid system in development. Novel signal transduction translates multiple extracellular signals into neural cell growth and differentiation. *Perspect. Dev. Neurobiol.* 5, 437-449.
- Haverkamp S., Ghosh K.K., Hirano A.A. and Wässle H. (2003). Immunocytochemical description of five bipolar cell types of the mouse retina. *J. Comp. Neurol.* 455, 463-476.
- Heinrichs S.C. and Richard D. (1999). The role of corticotropin-releasing factor and urocortin in the modulation of ingestive behavior. *Neuropeptides* 33, 350-359.
- Helboe L. and Moller M. (1999). Immunohistochemical localization of somatostatin receptor subtypes sst<sub>1</sub> and sst<sub>2</sub> in the rat retina. *Invest. Ophthalmol. Vis. Sci.* 40, 2376-2382.
- Helboe L., Stidsen C.E. and Moller M. (1998). Immunohistochemical and cytochemical localization of the somatostatin receptor subtype sst<sub>1</sub> in the somatostatinergic parvocellular neuronal system of the rat hypothalamus. *J. Neurosci.* 18, 4938-4945.
- Hökfelt T., Pernow B. and Wahren J. (2001). Substance P: a pioneer amongst neuropeptides. *J. Intern. Med.* 249, 27-40.
- Hökfelt T., Broberger C., Xu Z.Q., Sergeev V., Ubink R. and Diez M. (2000). Neuropeptides--an overview. *Neuropharmacology* 39, 1337-1356.
- Horsburgh G.M. and Sefton A.J. (1987). Cellular degeneration and synaptogenesis in the developing retina of the rat. *J. Comp. Neurol.* 263, 553-566.
- Hutsler J.J. and Chalupa L.M. (1994). Neuropeptide Y immunoreactivity identifies a regularly arrayed group of amacrine cells within the cat retina. *J. Comp. Neurol.* 346, 481-489.
- Hutsler J.J. and Chalupa L.M. (1995). Development of neuropeptide Y immunoreactive amacrine and ganglion cells in the pre- and postnatal cat retina. *J. Comp. Neurol.* 361, 152-164.
- Isayama T. and Zagon I.S. (1991). Localization of preproenkephalin A mRNA in the neonatal rat retina. *Brain Res. Bull.* 27, 805-808.
- Isayama T., McLaughlin P.J. and Zagon I.S. (1991). Endogenous opioids regulate cell proliferation in the retina of developing rat. *Brain Res.* 544, 79-85.
- Isayama T., Hurst W.J., McLaughlin P.J. and Zagon I.S. (1995). Ontogeny of the opioid growth factor, [Met<sup>5</sup>]-enkephalin, and its binding activity in the rat retina. *Vis. Neurosci.* 12, 939-950.
- Isayama T., McLaughlin P.J. and Zagon I.S. (1996). Ontogeny of preproenkephalin mRNA expression in the rat retina. *Vis. Neurosci.* 13, 695-704.
- Itoh N., Obata K., Yanaihara N. and Okamoto H. (1983). Human preprovasoactive intestinal polypeptide contains a novel PHI-27-like peptide, PHM-27. *Nature* 304, 547-549.

- Iwasaki Y., Kinoshita M., Ikeda K., Takamiya K. and Shiojima T. (1989). Trophic effect of various neuropeptides on the cultured ventral spinal cord of rat embryo. *Neurosci. Lett.* 101, 316-320.
- Iwasaki Y., Ikeda K., Ichikawa Y. and Igarashi O. (2001). Vasoactive intestinal peptide influences neurite outgrowth in cultured rat spinal cord neurons. *Neurol. Res.* 23, 851-854.
- Jaworski D.M. and Proctor M.D. (2000). Developmental regulation of pituitary adenylate cyclase-activating polypeptide and PAC(1) receptor mRNA expression in the rat central nervous system. *Dev. Brain Res.* 120, 27-39.
- Jen P.Y., Li W.W. and Yew D.T. (1994). Immunohistochemical localization of neuropeptide Y and somatostatin in human fetal retina. *Neuroscience* 60, 727-735.
- Johansson K., Bruun A., deVente J. and Ehinger B. (2000a). Immunohistochemical analysis of the developing inner plexiform layer in postnatal rat retina. *Invest. Ophthalmol. Vis. Sci.* 41, 305-313.
- Johansson K., Bruun A., Torngren M. and Ehinger B. (2000b). Development of glutamate receptor subunit 2 immunoreactivity in postnatal rat retina. *Vis. Neurosci.* 17, 737-742.
- Johansson O., Hökfelt T. and Elde R.P. (1984). Immunohistochemical distribution of somatostatin-like immunoreactivity in the central nervous system of the adult rat. *Neuroscience* 13, 265-339.
- Johnson J., Wong H., Walsh J.H. and Brecha N.C. (1998). Expression of the somatostatin subtype 2A receptor in the rabbit retina. *J. Comp. Neurol.* 393, 93-101.
- Johnson J., Wu V., Wong H., Walsh J.H. and Brecha N.C. (1999). Somatostatin receptor subtype 2A expression in the rat retina. *Neuroscience* 94, 675-683.
- Johnson J., Caravelli M.L. and Brecha N.C. (2001). Somatostatin inhibits calcium influx into rat rod bipolar cell axonal terminals. *Vis. Neurosci.* 18, 101-108.
- Jonsson G. and Hallman H. (1982). Response of central monoamine neurons following an early neurotoxic lesion. *Bibl. Anat.* 23, 76-92.
- Jotwani G., Itoh K. and Wadhwa S. (1994). Immunohistochemical localization of tyrosine hydroxylase, substance P, neuropeptide-Y and leucine-enkephalin in developing human retinal amacrine cells. *Dev. Brain Res.* 77, 285-289.
- Kaiser P.K. and Lipton S.A. (1990). VIP-mediated increase in cAMP prevents tetrodotoxin-induced retinal ganglion cell death in vitro. *Neuron* 5, 373-381.
- Kalil R.E. (1990). The influence of action potentials on the development of the central visual pathway in mammals. *J. Exp. Biol.* 153, 261-276.
- Karacay B., O'Dorisio M.S., Summers M. and Bruce J. (2000). Regulation of vasoactive intestinal peptide receptor expression in developing nervous systems. *Ann. NY. Acad. Sci.* 921, 165-174.
- Katz L.C. (1993). Coordinate activity in retinal and cortical development. *Curr. Opin. Neurobiol.* 3, 93-99.
- Kirsch B. and Leonhardt H. (1979). Demonstration of a somatostatin-like activity in retinal cells of the rat. *Cell. Tissue Res.* 204, 127-140.
- Koh S.M. (2000). VIP enhances the differentiation of retinal pigment epithelium in culture: from cAMP and pp60(c-src) to melanogenesis and development of fluid transport capacity. *Prog. Retin. Eye Res.* 19, 669-688.
- Kolb H., Linberg K.A. and Fisher S.K. (1992). Neurons of the human retina: a Golgi study. *J. Comp. Neurol.* 318, 147-187.
- Kolb H., Nelson R., Ahnelt P. and Cuenca N. (2001). Cellular organization of the vertebrate retina. *Prog. Brain Res.* 131, 3-26.
- Koulen P. (1997). Vesicular acetylcholine transporter (VACht): a cellular marker in rat retinal development. *Neuroreport* 8, 2845-2848.
- Koulen P. (1999). Localization of synapse-associated proteins during postnatal development of the rat retina. *Eur. J. Neurosci.* 11, 2007-2018.
- Koulen P., Sassoè-Pognetto M., Grünert U. and Wässle H. (1996). Selective clustering of GABA(A) and glycine receptors in the mammalian retina. *J. Neurosci.* 16, 2127-2140.
- Koulen P., Brandstätter J.H., Kroger S., Enz R., Bormann J. and Wässle H. (1997). Immunocytochemical localization of the GABA(C) receptor rho subunits in the cat, goldfish, and chicken retina. *J. Comp. Neurol.* 380, 520-532.
- Koulen P., Brandstätter J.H., Enz R., Bormann J. and Wässle H. (1998a). Synaptic clustering of GABA(C) receptor rho-subunits in the rat retina. *Eur. J. Neurosci.* 10, 115-127.
- Koulen P., Malitschek B., Kuhn R., Bettler B., Wässle H. and Brandstätter J.H. (1998b). Presynaptic and postsynaptic localization of GABA(B) receptors in neurons of the rat retina. *Eur. J. Neurosci.* 10, 1446-1456.
- Kubek M.J. and Garg B.P. (2002). Thyrotropin-releasing hormone in the treatment of intractable epilepsy. *Pediatr. Neurol.* 26, 9-17.
- Kungel M., Piechotta K., Rietzel H.J. and Friauf E. (1997). Influence of the neuropeptide somatostatin on the development of dendritic morphology: a cysteamine-depletion study in the rat auditory brainstem. *Dev. Brain Res.* 101, 107-114.
- Kwong W.H., Chan W.Y., Lee K.K., Fan M. and Yew D.T. (2000). Neurotransmitters, neuropeptides and calcium binding proteins in developing human cerebellum: a review. *Histochem. J.* 32, 521-534.
- Lanneau C., Viollet C., Faivre-Bauman A., Loudes C., Kordon C., Epelbaum J. and Gardette R. (1998). Somatostatin receptor subtypes sst1 and sst2 elicit opposite effects on the response to glutamate of mouse hypothalamic neurones: an electrophysiological and single cell RT-PCR study. *Eur. J. Neurosci.* 10, 204-212.
- Lanneau C., Bluet-Pajot M.T., Zizzari P., Csaba Z., Dournaud P., Helboe L., Hoyer D., Pellegrini E., Tannenbaum G.S., Epelbaum J. and Gardette R. (2000). Involvement of the sst1 somatostatin receptor subtype in the intrahypothalamic neuronal network regulating growth hormone secretion: an in vitro and in vivo antisense study. *Endocrinology* 141, 967-979.
- Larhammar D. (1996). Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. *Regul. Pept.* 62, 1-11.
- Lariviere W.R. and Melzack R. (2000). The role of corticotropin-releasing factor in pain and analgesia. *Pain* 84, 1-12.
- Lee E.J., Park S.H., Kim I.B., Kang W.S., Oh S.J. and Chun M.H. (2002). Light- and electron-microscopic analysis of vasoactive intestinal polypeptide-immunoreactive amacrine cells in the guinea pig retina. *J. Comp. Neurol.* 445, 325-335.
- Leroux P., Bodenat C., Bologna E., Gonzalez B. and Vaudry H. (1995). Transient expression of somatostatin receptors in the brain during development. *Ciba Found. Symp.* 190, 127-137.
- Levy A., Gal R., Granoth R., Dreznik Z., Fridkin M. and Gozes I. (2002). In vitro and in vivo treatment of colon cancer by VIP antagonists. Vasoactive intestinal peptide. *Regul. Pept.* 109, 127-133.
- Lindholm D., Skoglosa Y. and Takei N. (1998). Developmental regulation of pituitary adenylate cyclase activating polypeptide (PACAP) and its receptor 1 in rat brain, function of PACAP as a neurotrophic factor. *Ann. N. Y. Acad. Sci.* 865, 189-196.
- Lioudyno M., Skoglosa Y., Takei N. and Lindholm D. (1998). Pituitary adenylate cyclase-activating polypeptide (PACAP) protects dorsal

## Peptides in retinal development

- root ganglion neurons from death and induces calcitonin gene-related peptide (CGRP) immunoreactivity in vitro. *J. Neurosci. Res.* 51, 243-256.
- Livesey F.J. and Cepko C.L. (2001). Vertebrate neural cell-fate determination: lessons from the retina. *Nat. Rev. Neurosci.* 2, 109-118.
- Lockerbie R.O., Beaujouan J.C., Saffroy M. and Glowinski J. (1988). An isolated growth cone-enriched fraction from developing rat brain has substance P binding sites. *Brain Res.* 468, 1-9.
- Lundberg J.M. (1996). Pharmacology of cotransmission in the autonomic nervous system: integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. *Pharmacol. Rev.* 48, 113-178.
- Lyons M.K., Anderson R.E. and Meyer F.B. (1991). Corticotropin releasing factor antagonist reduces ischemic hippocampal neuronal injury. *Brain Res.* 545, 339-342.
- Lyser K.M., Chernomorsky R., Michalopoulos C. and Twersky L.H. (1999). Horizontal cell differentiation in the retina of the Brazilian opossum, *Monodelphis domestica*. *Int. J. Dev. Neurosci.* 17, 225-237.
- MacKenzie A. and Quinn J. (2002). A yeast artificial chromosome containing the human preprotachykinin-A gene expresses substance P in mice and drives appropriate marker-gene expression during early brain embryogenesis. *Mol. Cell. Neurosci.* 19, 72-87.
- Magistretti P.J., Cardinaux J.R. and Martin J.L. (1998). VIP and PACAP in the CNS: regulators of glial energy metabolism and modulators of glutamatergic signaling. *Ann. NY. Acad. Sci.* 865, 213-225.
- Manni L., Aloe L., Tirassa P., Finn A. and Lundberg T. (2001). Cholecystokinin-8 promotes recovery of sympathectomy induced by 6-hydroxydopamine in adult mice. *Neuroreport* 12, 1621-1627.
- Marshak D.W. (1989). Peptidergic neurons of the macaque monkey retina. *Neurosci. Res. Suppl.* 10, S117-S130.
- Masland R.H. (1977). Maturation of function in the developing rabbit retina. *J. Comp. Neurol.* 175, 275-286.
- Masland R.H. (2001a). Neuronal diversity in the retina. *Curr. Opin. Neurobiol.* 11, 431-436.
- Masland R.H. (2001b). The fundamental plan of the retina. *Nat. Neurosci.* 4, 877-886.
- McArdle C.B., Dowling J.E. and Masland R.H. (1977). Development of outer segments and synapses in the rabbit retina. *J. Comp. Neurol.* 175, 253-274.
- Messersmith E.K. and Redburn D.A. (1993). The role of GABA during development of the outer retina in the rabbit. *Neurochem. Res.* 18, 463-470.
- Mey J. and Thanos S. (2000). Development of the visual system of the chick. I. Cell differentiation and histogenesis. *Brain Res. Brain Res. Rev.* 32, 343-379.
- Michel M.C., Beck-Sickingler A., Cox H., Doods H.N., Herzog H., Larhammar D., Quirion R., Schwartz T. and Westfall T. (1998). XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. *Pharmacol. Rev.* 50, 143-150.
- Mitrofanis J., Maslim J. and Stone J. (1989a). Ontogeny of catecholaminergic and cholinergic cell distributions in the cat's retina. *J. Comp. Neurol.* 289, 228-246.
- Mitrofanis J., Robinson S.R. and Provis J.M. (1989b). Somatostatinergic neurones of the developing human and cat retinae. *Neurosci. Lett.* 104, 209-216.
- Mitrofanis J., Robinson S.R. and Ashwell K. (1992). Development of catecholaminergic, indoleamine-accumulating and NADPH-diaphorase amacrine cells in rabbit retinae. *J. Comp. Neurol.* 319, 560-585.
- Morara S., Marcotti W., Provini L. and Rosina A. (1997). Neuropeptide Y (NPY) expression is up-regulated in the rat inferior olive during development. *Neuroreport* 8, 3743-3747.
- Müller J.M., Lelievre V., Becq-Giraudon L. and Meunier A.C. (1995). VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment. *Mol. Neurobiol.* 10, 115-134.
- Nakai K. and Kasamatsu T. (1984). Accelerated regeneration of central catecholamine fibers in cat occipital cortex: effects of substance P. *Brain Res.* 323, 374-379.
- Narumi S. and Fujita T. (1978). Stimulatory effects of substance P and nerve growth factor (NGF) on neurite outgrowth in embryonic chick dorsal root ganglia. *Neuropharmacology* 17, 73-76.
- Nguyen-Legros J., Versaux-Botteri C. and Vigny A. (1986). Early development of tyrosine hydroxylase-like and substance P-like immunoreactivity in the human fetal retina. *Hum. Neurobiol.* 5, 115-120.
- Nishimura Y. and Rakic P. (1987). Synaptogenesis in the primate retina proceeds from the ganglion cells towards the photoreceptors. *Neurosci. Res. Suppl.* 6, S253-S268.
- Nock B., Giordano A.L., Moore B.W. and Cicero T.J. (1993). Properties of the putative epsilon opioid receptor: identification in rat, guinea pig, cow, pig and chicken brain. *J. Pharmacol. Exp. Ther.* 264, 349-359.
- Obrietan K. and van den Pol A.N. (1996). Neuropeptide Y depresses GABA-mediated calcium transients in developing suprachiasmatic nucleus neurons: a novel form of calcium long-term depression. *J. Neurosci.* 16, 3521-3533.
- Oh S.J., D'Angelo I., Lee E.J., Chun M.H. and Brecha N.C. (2002). Distribution and synaptic connectivity of neuropeptide Y-immunoreactive amacrine cells in the rat retina. *J. Comp. Neurol.* 446, 219-234.
- O'Leary D.D., Fawcett J.W. and Cowan W.M. (1986). Topographic targeting errors in the retinocollicular projection and their elimination by selective ganglion cell death. *J. Neurosci.* 6, 3692-3705.
- Olianas M.C., Ingiani A., Sogos V. and Onali P. (1997). Expression of pituitary adenylate cyclase-activating polypeptide (PACAP) receptors and PACAP in human fetal retina. *J. Neurochem.* 69, 1213-1218.
- Osborne N.N. and Perry V.H. (1985). Effect of neonatal optic nerve transection on some classes of amacrine cells in the rat retina. *Brain Res.* 343, 230-235.
- Otsuka M. and Yoshioka K. (1993). Neurotransmitter functions of mammalian tachykinins. *Physiol. Rev.* 73, 229-308.
- Oyamada H., Takatsuji K., Senba E., Mantyh P.W. and Tohyama M. (1999). Postnatal development of NK1, NK2, and NK3 neurokinin receptors expression in the rat retina. *Dev. Brain Res.* 117, 59-70.
- Patel Y.C. (1999). Somatostatin and its receptor family. *Front. Neuroendocrinol.* 20, 157-198.
- Perry V.H., Henderson Z. and Linden R. (1983). Postnatal changes in retinal ganglion cell and optic axon populations in the pigmented rat. *J. Comp. Neurol.* 219, 356-368.
- Petrucci C., Cervia D., Buzzi M., Biondi C. and Bagnoli P. (2000). Somatostatin-induced control of cytosolic free calcium in pituitary tumour cells. *Br. J. Pharmacol.* 129, 471-484.
- Petrucci C., Resta V., Fieni F., Bigiani A. and Bagnoli P. (2001). Modulation of potassium current and calcium influx by somatostatin

- in rod bipolar cells isolated from the rabbit retina via sst<sub>2</sub> receptors. *Naunyn Schmiedebergs Arch. Pharmacol.* 363, 680-694.
- Pincus D.W., DiCicco-Bloom E.M. and Black I.B. (1990). Vasoactive intestinal peptide regulation of neuroblast mitosis and survival: role of cAMP. *Brain Res.* 514, 355-357.
- Potts R.A., Dreher B. and Bennett M.R. (1982). The loss of ganglion cells in the developing retina of the rat. *Brain Res.* 255, 481-486.
- Pow D.V. and Barnett N.L. (2000). Developmental expression of excitatory amino acid transporter 5: a photoreceptor and bipolar cell glutamate transporter in rat retina. *Neurosci. Lett.* 280, 21-24.
- Pradayrol L., Jornvall H., Mutt V. and Ribet A. (1980). N-terminally extended somatostatin: the primary structure of somatostatin-28. *FEBS Lett.* 109, 55-58.
- Provis J.M., Diaz C.M. and Dreher B. (1998). Ontogeny of the primate fovea: a central issue in retinal development. *Prog. Neurobiol.* 54, 549-580.
- Przewlocki R. and Przewlocka B. (2001). Opioids in chronic pain. *Eur. J. Pharmacol.* 429, 79-91.
- Raffa R.B. (1998). Possible role(s) of neurokinins in CNS development and neurodegenerative or other disorders. *Neurosci. Biobehav. Rev.* 22, 789-813.
- Rapaport D.H. and Vietri A.J. (1991). Identity of cells produced by two stages of cytogenesis in the postnatal cat retina. *J. Comp. Neurol.* 312, 341-352.
- Reed G., Moeller I., Mendelsohn F.A. and Small D.H. (1996). A novel action of angiotensin peptides in inhibiting neurite outgrowth from isolated chick sympathetic neurons in culture. *Neurosci. Lett.* 210, 209-212.
- Reed H.E., Cutler D.J., Brown T.M., Brown J., Coen C.W. and Piggins H.D. (2002). Effects of vasoactive intestinal polypeptide on neurones of the rat suprachiasmatic nuclei in vitro. *J. Neuroendocrinol.* 14, 639-646.
- Rees S. and Bainbridge A. (1992). The structural and neurochemical development of the fetal guinea pig retina and optic nerve in experimental growth retardation. *Int. J. Dev. Neurosci.* 10, 93-108.
- Reese B.E. and Galli-Resta L. (2002). The role of tangential dispersion in retinal mosaic formation. *Prog. Retin. Eye Res.* 21, 153-168.
- Reul J.M. and Holsboer F. (2002). Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. *Curr. Opin. Pharmacol.* 2, 23-33.
- Rhie D.J., Yi S.Y., Hahn S.J., Sim S.S., Jo Y.H. and Kim M.S. (1999). Somatostatin potentiates voltage-dependent K<sup>+</sup> and Ca<sup>2+</sup> channel expression induced by nerve growth factor in PC12 cells. *Dev. Brain Res.* 112, 267-274.
- Rich K.A., Zhan Y. and Blanks J.C. (1997). Migration and synaptogenesis of cone photoreceptors in the developing mouse retina. *J. Comp. Neurol.* 388, 47-63.
- Rupniak N.M. (2002). Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. *Curr. Opin. Investig. Drugs.* 3, 257-261.
- Said S.I. and Mutt V. (1970). Potent peripheral and splanchnic vasodilator peptide from normal gut. *Nature* 225, 863-864.
- Sakiyama T., Kuwayama Y., Ishimoto I., Sasaoka A., Shiosaka S., Tohyama M., Manabe R. and Shiotani Y. (1984). Ontogeny of substance P-containing structures in the ocular tissue of the rat: an immunohistochemical analysis. *Brain Res.* 315, 275-281.
- Sandmann D., Engelmann R. and Peichl L. (1997). Starburst cholinergic amacrine cells in the tree shrew retina. *J. Comp. Neurol.* 389, 161-176.
- Sarthy P.V. and Bacon W. (1985). Developmental expression of a synaptic vesicle-specific protein in the rat retina. *Dev. Biol.* 112, 284-291.
- Sassoè-Pognetto M. and Wässle H. (1997). Synaptogenesis in the rat retina: subcellular localization of glycine receptors, GABA(A) receptors, and the anchoring protein gephyrin. *J. Comp. Neurol.* 381, 158-174.
- Schnitzer J. (1990). Postnatal gliogenesis in the nerve fiber layer of the rabbit retina: an autoradiographic study. *J. Comp. Neurol.* 292, 551-562.
- Schwartz J.P., Ji Z. and Epelbaum J. (1998). Somatostatin as a neurotrophic factor. Which receptor/second messenger transduction system is involved? *Perspect. Dev. Neurobiol.* 5, 427-435.
- Servoss S.J., Lee S.J., Gibney G., Gozes I., Brenneman D.E. and Hill J.M. (2001). IGF-I as a mediator of VIP/activity-dependent neurotrophic factor-stimulated embryonic growth. *Endocrinology* 142, 3348-3353.
- Sharma R.K. and Johnson D.A. (2000) Molecular signals for development of neuronal circuitry in the retina. *Neurochem. Res.* 25, 1257-1263.
- Shoge K., Mishima H.K., Saitoh T., Ishihara K., Tamura Y., Shiomi H. and Sasa M. (1998). Protective effects of vasoactive intestinal peptide against delayed glutamate neurotoxicity in cultured retina. *Brain Res.* 809, 127-136.
- Shoge K., Mishima H.K., Saitoh T., Ishihara K., Tamura Y., Shiomi H. and Sasa M. (1999). Attenuation by PACAP of glutamate-induced neurotoxicity in cultured retinal neurons. *Brain Res.* 839, 66-73.
- Siegel A., Roeling T.A., Gregg T.R. and Kruk M.R. (1999). Neuropharmacology of brain-stimulation-evoked aggression. *Neurosci. Biobehav. Rev.* 23, 359-389.
- Silveira M.S., Costa M.R., Bozza M. and Linden R. (2002). Pituitary adenyl cyclase-activating polypeptide prevents induced cell death in retinal tissue through activation of cyclic AMP-dependent protein kinase. *J. Biol. Chem.* 277, 16075-16080.
- Simon D.K. and O'Leary D.D. (1992). Development of topographic order in the mammalian retinocollicular projection. *J. Neurosci.* 12, 1212-1232.
- Skoglosa Y., Takei N. and Lindholm D. (1999). Distribution of pituitary adenylate cyclase activating polypeptide mRNA in the developing rat brain. *Brain Res. Mol. Brain Res.* 65, 1-13.
- Spira A.W., Shimizu Y. and Rorstad O.P. (1984). Localization, chromatographic characterization, and development of somatostatin-like immunoreactivity in the guinea pig retina. *J. Neurosci.* 4, 3069-3079.
- Spong C.Y., Lee S.J., McCune S.K., Gibney G., Abebe D.T., Brenneman D.E. and Hill J.M. (1999). Regulation of postimplantation mouse embryonic growth by maternal vasoactive intestinal peptide. *Ann. N. Y. Acad. Sci.* 897, 101-108.
- Steiner H. and Gerfen C.R. (1998). Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. *Exp. Brain Res.* 123, 60-76.
- Stone J. (1988). The origins of the cells of vertebrate retina. *Progr. Ret. Res.* 7, 1-19.
- Stone R.A., Laties A.M., Raviola E. and Wiesel T.N. (1988). Increase in retinal vasoactive intestinal polypeptide after eyelid fusion in primates. *Proc. Natl. Acad. Sci. USA* 85, 257-260.
- Strettoi E. and Masland R.H. (1996). The number of unidentified amacrine cells in the mammalian retina. *Proc. Natl. Acad. Sci. USA* 93, 14906-14911.

*Peptides in retinal development*

- Strettoi E., Porciatti V., Falsini B., Pignatelli V. and Rossi C. (2002). Morphological and functional abnormalities in the inner retina of the rd/rd mouse. *J. Neurosci.* 22, 5492-5504.
- Strijbos P.J., Relton J.K. and Rothwell N.J. (1994). Corticotrophin-releasing factor antagonist inhibits neuronal damage induced by focal cerebral ischaemia or activation of NMDA receptors in the rat brain. *Brain Res.* 656, 405-408.
- Suh J., Lu N., Nicot A., Tatsuno I. and DiCicco-Bloom E. (2001). PACAP is an anti-mitogenic signal in developing cerebral cortex. *Nat. Neurosci.* 4, 123-124.
- Takahashi L.K. (2001). Role of CRF(1) and CRF(2) receptors in fear and anxiety. *Neurosci. Biobehav. Rev.* 25, 627-636.
- Taniwaki T. and Schwartz J.P. (1995). Somatostatin enhances neurofilament expression and neurite outgrowth in cultured rat cerebellar granule cells. *Dev. Brain Res.* 88, 109-116.
- Taoka M., Song S.Y., Kubota M., Minegishi A., Yamakuni T. and Konishi S. (1996). Increased level of neurokinin-1 tachykinin receptor gene expression during early postnatal development of rat brain. *Neuroscience* 74, 845-853.
- Terubayashi H., Okamura H., Fujisawa H., Itoi M., Yanaihara N. and Ibata Y. (1982). Postnatal development of vasoactive intestinal polypeptide immunoreactive amacrine cells in the rat retina. *Neurosci. Lett.* 33, 259-264.
- Thorsell A. and Heilig M. (2002). Diverse functions of neuropeptide Y revealed using genetically modified animals. *Neuropeptides* 36, 182-193.
- Traina G., Petrucci C., Gargini C. and Bagnoli P. (1998). Somatostatin enhances neurite outgrowth in PC12 cells. *Brain Res. Dev. Brain Res.* 111, 223-230.
- Tseng L.F., Henneberry B. and Collins K.A. (1995). The antinociception induced by beta-endorphin administered intrathecally is mediated by the activation of mu- and kappa-opioid receptors in the rat. *Naunyn Schmiedeberg's Arch. Pharmacol.* 351, 464-468.
- Ubink R. and Hökfelt T. (2000). Neuropeptide Y expression in Schwann cell precursors. *Glia* 32, 71-83.
- Vaney D.I., Whittington G.E. and Young H.M. (1989). The morphology and topographic distribution of substance-P-like immunoreactive amacrine cells in the cat retina. *Proc. R. Soc. Lond. B Biol. Sci.* 237, 471-488.
- Vasilaki A., Gardette R., Epelbaum J. and Thermos K. (2001). NADPH-diaphorase colocalization with somatostatin receptor subtypes  $sst_{2A}$  and  $sst_{2B}$  in the retina. *Invest. Ophthalmol. Vis. Sci.* 42, 1600-1609.
- Vasilaki A., Georgoussi Z. and Thermos K. (2003). Somatostatin receptors ( $sst_2$ ) are coupled to Go and modulate GTPase activity in the rabbit retina. *J. Neurochem.* 84, 625-632.
- Vaudry D., Gonzalez B.J., Basille M., Fournier A. and Vaudry H. (1999). Neurotrophic activity of pituitary adenylate cyclase-activating polypeptide on rat cerebellar cortex during development. *Proc. Natl. Acad. Sci. USA* 96, 9415-9420.
- Vaudry D., Rousselle C., Basille M., Falluel-Morel A., Pamantung T.F., Fontaine M., Fournier A., Vaudry H. and Gonzalez B.J. (2002a). Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death. *Proc. Natl. Acad. Sci. USA.* 99, 6398-6403.
- Vaudry D., Pamantung T.F., Basille M., Rousselle C., Fournier A., Vaudry H., Beauvillain J.C. and Gonzalez B.J. (2002b). PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis. *Eur. J. Neurosci.* 15, 1451-1460.
- Veruki M.L. and Yeh H.H. (1992). Vasoactive intestinal polypeptide modulates GABAA receptor function in bipolar cells and ganglion cells of the rat retina. *J. Neurophysiol.* 67, 791-797.
- Vigh J., Banvolgyi T. and Wilhelm M. (2000). Amacrine cells of the anuran retina: morphology, chemical neuroanatomy, and physiology. *Microsc. Res. Tech.* 50, 373-383.
- Wadhwa S., Rizvi T.A. and Bijlani V. (1988). Substance P-immunoreactivity in the developing human retinogeniculate pathway. *Neurosci. Lett.* 89, 25-30.
- Wamsley J.K., Palacios J.M. and Kuhar M.J. (1981). Autoradiographic localization of opioid receptors in the mammalian retina. *Neurosci. Lett.* 27, 19-24.
- Waschek J.A. (2002). Multiple actions of pituitary adenylate cyclase activating peptide in nervous system development and regeneration. *Dev. Neurosci.* 24, 14-23.
- Waschek J.A., DiCicco-Bloom E.M., Lelievre V., Zhou X. and Hu Z. (2000). PACAP action in nervous system development, regeneration, and neuroblastoma cell proliferation. *Ann. N. Y. Acad. Sci.* 921, 129-136.
- Wässle H. and Boycott B.B. (1991). Functional architecture of the mammalian retina. *Physiol. Rev.* 71, 447-480.
- Wässle H., Yamashita M., Greferath U., Grünert U. and Müller F. (1991). The rod bipolar cell of the mammalian retina. *Vis. Neurosci.* 7, 99-112.
- Webster M.J. and Rowe M.H. (1991). Disruption of developmental timing in the albino rat retina. *J. Comp. Neurol.* 307, 460-474.
- White C.A. and Chalupa L.M. (1991). Subgroup of alpha ganglion cells in the adult cat retina is immunoreactive for somatostatin. *J. Comp. Neurol.* 304, 1-13.
- White C.A. and Chalupa L.M. (1992). Ontogeny of somatostatin immunoreactivity in the cat retina. *J. Comp. Neurol.* 317, 129-144.
- White D.M. (1998). Contribution of neurotrophin-3 to the neuropeptide Y-induced increase in neurite outgrowth of rat dorsal root ganglion cells. *Neuroscience* 86, 257-263.
- Williams R.W., Bastiani M.J., Lia B. and Chalupa L.M. (1986). Growth cones, dying axons, and developmental fluctuations in the fiber population of the cat's optic nerve. *J. Comp. Neurol.* 246, 32-69.
- Wong R.O. (1995). Effects of glutamate and its analogs on intracellular calcium levels in the developing retina. *Vis. Neurosci.* 12, 907-917.
- Wong R.O. (1998). Calcium imaging and multielectrode recordings of global patterns of activity in the developing nervous system. *Histochem. J.* 30, 217-229.
- Wong R.O., Meister M. and Shatz C.J. (1993). Transient period of correlated bursting activity during development of the mammalian retina. *Neuron* 11, 923-938.
- Wong R.O., Chernjavsky A., Smith S.J. and Shatz C.J. (1995). Early functional neural networks in the developing retina. *Nature* 374, 716-718.
- Wong W.T., Myhr K.L., Miller E.D. and Wong R.O. (2000). Developmental changes in the neurotransmitter regulation of correlated spontaneous retinal activity. *J. Neurosci.* 20, 351-360.
- Xiang Z., Jiang L. and Kang Z. (2001). Transient expression of somatostatin mRNA in developing ganglion cell layers of rat retina. *Dev. Brain Res.* 128, 25-33.
- Yacubova E. and Komuro H. (2002). Stage-specific control of neuronal migration by somatostatin. *Nature* 415, 77-81.
- Yamasaki E.N. and Ramoa A.S. (1993). Dendritic remodeling of retinal ganglion cells during development of the rat. *J. Comp. Neurol.* 329, 277-289.

- Yeh H.H. and Olschowka J.A. (1989). A system of corticotropin releasing factor-containing amacrine cells in the rat retina. *Neuroscience* 33, 229-240.
- Yew D.T., Luo C.B., Zheng D.R., Guan Y.L., Tsang D. and Stadlin A. (1991). Immunohistochemical localization of substance P, enkephalin and serotonin in the developing human retina. *J. Hirnforsch.* 32, 61-67.
- Yew D.T., Chan W.Y., Luo C.B., Zheng D.R. and Yu M.C. (1999). Neurotransmitters and neuropeptides in the developing human central nervous system. A review. *Biol. Signals Recept.* 8, 149-159.
- Yoon H.Z., Yan Y., Geng Y. and Higgins R.D. (2002). Neuropeptide Y expression in a mouse model of oxygen-induced retinopathy. *Clin. Exp. Ophthalmol.* 30, 424-429.
- Zagon I.S., Verderame M.F. and McLaughlin P.J. (2002). The biology of the opioid growth factor receptor (OGFr). *Brain Res. Brain Res. Rev.* 38, 351-376.
- Zalutsky R.A. and Miller R.F. (1990a). The physiology of somatostatin in the rabbit retina. *J. Neurosci.* 10, 383-393.
- Zalutsky R.A. and Miller R.F. (1990b). The physiology of substance P in the rabbit retina. *J. Neurosci.* 10, 394-402.
- Zhang D. and Yeh H.H. (1991). Corticotropin releasing factor-like immunoreactivity (CRF-LI) in horizontal cells of the developing rat retina. *Vis. Neurosci.* 6, 383-391.
- Zhang D. and Yeh H.H. (1992). Substance-P-like immunoreactive amacrine cells in the adult and the developing rat retina. *Dev. Brain Res.* 68, 55-65.
- Zhang D.R., Gallagher M., Sladek C.D. and Yeh H.H. (1990). Postnatal development of corticotropin releasing factor-like immunoreactive amacrine cells in the rat retina. *Brain Res. Dev. Brain. Res.* 51, 185-194.
- Zhou C.J., Shioda S., Yada T., Inagaki N., Pleasure S.J. and Kikuyama S. (2002). PACAP and its receptors exert pleiotropic effects in the nervous system by activating multiple signaling pathways. *Curr. Protein Pept. Sci.* 3, 423-439.
- Zhou Z.J. (2001a). A critical role of the strychnine-sensitive glycinergic system in spontaneous retinal waves of the developing rabbit. *J. Neurosci.* 21, 5158-5168.
- Zhou Z.J. (2001b). The function of the cholinergic system in the developing mammalian retina. *Prog. Brain Res.* 131, 599-613.
- Zhou Z.J. and Zao D. (2000). Coordinated transitions in neurotransmitter systems for the initiation and propagation of spontaneous retinal waves. *J. Neurosci.* 20, 6570-6577.
- Zupan V., Nehlig A., Evrard P. and Gressens P. (2000). Prenatal blockade of vasoactive intestinal peptide alters cell death and synaptic equipment in the murine neocortex. *Pediatr. Res.* 47, 53-63.

Accepted May 5, 2003